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PREFACE 
Developing countries bear the burden of tuberculosis infections. In particular, South Africa 
ranks high among these countries with KwaZulu-Natal province having the highest 
incidence. This high prevalence of tuberculosis (TB) infection is associated with the 
increasing human immunodeficiency virus (HIV). Whilst many research studies have been 
conducted on TB, most have focused on pulmonary TB (PTB) or other body parts rather 
than on the breast. It appears like the presence of breast TB (BTB) has been overlooked by 
research teams. Sadly, there is no national breast cancer screening, and women who have 
BTB end up with complications from various factors including: being frightened to seek help 
because of the belief that it might be cancer; being misdiagnosed by their healthcare-worker 
as having simple mastitis; and being misdiagnosed at hospital as having pyogenic breast 
infection. It is for these factors that we embarked on attempting to raise awareness of the 
disease, specifically to study the radiological appearances on various radiology modalities, 
and to improve pertinent differentiating features between BTB and breast cancer, with the 
aim of increasing practitioner’s level of confidence in diagnosing the condition. 
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ABSTRACT 
Women in KwaZulu-Natal Province, South Africa, are at high risk of developing breast 
tuberculosis (BTB) due to the increased incidence of HIV. However, there is a general lack 
of knowledge regarding the various diseases that can affect the breast. This is compounded 
by lack of the national breast screening program. As a result, many patients with breast 
cancer (BCA) and BTB are initially misdiagnosed by clinicians. It was evident from the 
study that much still has to be done in educating the public and healthcare workers about 
breast diseases.  
This project endeavoured to compare the effectiveness of various radiological technologies 
to identify breast problems. The study consisted of three phases all based at Ethekwini 
Municipality tertiary referral hospitals. The first phase aimed to determine the prevalence of 
the BTB using retrospective data over a period of 13 years. The same data further provided 
information of the clinical and radiological manifestations of BTB. This study concluded 
that while BTB is not common, it shares the clinical and radiology features with BCA, and 
is difficult to diagnose with current pathology methods.  
The second phase was done prospectively by recruiting patients who were newly diagnosed 
with BTB. The aim was to evaluate the use of modern imaging techniques to further describe 
the radiology patterns of BTB and to determine the radiological parameters that may be used 
in disease monitoring. The results provided insight into disease extent, and showed that it is 
usually more severe than perceived with current diagnostic methods.  
The third phase was performed using retrospective image analysis of patients who had BCA 
and BTB by using modern radiology techniques. The purpose was to identify the salient 
features that can differentiate BTB from the BCA. Several radiology parameters were 
identified as possible biomarkers for differentiation between the two conditions. The 
knowledge of their respective features would aid in the timeous diagnosis of both conditions, 
particularly in cases where the pathology results are inconclusive for various reasons.  
Overall the study highlights the lack of evidence based information on BTB.  
Recommendations and conclusions are provided in the last chapter. 
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CHAPTER 1 
INTRODUCTION 
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INTRODUCTION 
EXTRAPULMONARY TUBERCULOSIS 
It is estimated that in 2014, 9.6 million people were infected with Mycobacterium 
tuberculosis worldwide, the causative agent of tuberculosis (TB), and that the prevalence 
had increased since the previous year, 2013, when there were 9.0 million estimated cases 
(World Health Organisation. 2014, 2015). Although TB may affect any organ in the body, 
pulmonary tuberculosis (PTB) accounts for 80% of all cases (Akbulut et al. 2011; Centre for 
Disease Control and Prevention. 2013; Kulchavenya 2014). Extrapulmonary tuberculosis 
(EPTB) affects organs outside the lungs and has a reported incidence of 18-20% (Akbulut et 
al. 2011; Leeds et al. 2012; Mirsaeidi et al. 2007). The reported incidence of EPTB varies, 
depending on the geographical location and socioeconomic status of the population under 
study. Gunal et al. (2011) found the most common types of EPTB in Turkey to be 
genitourinary TB (27.2%) and meningeal TB (19.4%), with the other types ranging in 
incidence from 9.7% to 10.7% during the period 2001-2007 (Gunal et al. 2011). In the 
United States, the spectrum of EPTB from 1993-2006 was found to include lymphatic 
(40.4%), pleural (19.8%), bone and joint (11.3%), genitourinary (6.5%), meningeal (5.4%), 
peritoneal (4.9%) and unclassified EPTB (11.8%) (Peto et al. 2009).  
Meningeal TB and disseminated TB are more severe forms of TB and occur most commonly 
in children and immunocompromised adults (Aurum Institute 2013). Disseminated TB 
follows the widespread haematogenous spread of TB bacilli, which may be due to an 
exacerbation of recent primary infection or a complication of a pre-existing tuberculous 
focus which has eroded into a blood-vessel (Aurum Institute 2013). 
The impact of HIV on EPTB 
There has been a resurgence of EPTB in last 33 years due to the worldwide increasing 
incidence of Human Immune Deficiency Virus (HIV) infection (Leeds et al. 2012). The 
severity of the immunodeficiency in HIV infected individuals has led to the increased 
susceptibility to opportunistic infections, including TB (Department of Health South Africa. 
2009). The level of immunosuppression determines the nature of opportunistic infections. 
EPTB occurs more frequently in patients with a low CD4 count of < 100 
3
cells/mm3 (Department of Health South Africa. 2009). The development of EPTB in a HIV 
infected patient has been classified as WHO stage 4 (World Health Organization. 2005). 
BREAST TUBERCULOSIS 
Among other forms of tuberculosis infections, TB of the breast occurs and was initially 
described in 1829 by Sir Astley Cooper, an English surgeon and anatomist in 1829. In his 
two-part book entitled “Illustrations of diseases of the breast”, in a section named 
“Scrofulous Tumours of the Breast” he described finding tumours in the breasts of young 
women with enlarged cervical glands. He suggested that the tumours were of the 
inflammatory nature and were not to be regarded as malignant (Cooper 1829). Other reports 
and case series followed. The first classification was by Velpeau A (1854), who classified 
breast tuberculosis (BTB) into three forms: a) disseminated tubercles; b) multiple lymphatic 
tumours; and c) lymphatic suppurating (or caseating) tumours. To this point management 
consisted of the surgical removal of the diseased breast or breast tissue, and the diagnosis 
was based on clinical and surgical findings only. The first histological diagnosis of BTB was 
made by Lancereaux and Charley (1860) when they studied the structure of the removed part 
of the breast under the microscope . Subsequently, histological and bacteriological evidence 
for the diagnosis was reported by Gautier from his thesis in which he analysed seventy-seven 
previously published cases. He demonstrated the presence of tubercles containing giant cells 
(Gautier 1896). Around the same period, Dubar L-E (1881) reclassified the disease based 
on the microscopic and the histological appearances, classifying BTB as Isolated or 
disseminated nodular TB; and confluent TB on anatomical pathological grounds. Much later, 
McKeown and Wilkinson (1952) re-classified BTB into five types: nodular, disseminated, 
sclerosing, acute miliary tuberculous mastitis and tuberculous mastitis obliterans. They 
based their classifications on the clinical presentation reported in five case series they 
reviewed. The most recent formal classification is that of Tewari and Shukla (2005) who 
classified BTB into nodular-caseous, disseminated/confluent and abscess varieties. They 
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found nodular-caseous variety to be the most common. The two classifications are compared 
in Table 1.1 below. 
The route of breast infection 
BTB is termed primary if there is no other demonstrable focus elsewhere in the body. Several 
isolated cases of primary BTB have been reported since 1999 (Bhosale 2012; Chalazonitis 
et al. 2003; Chauhan et al. 2006; Gupta et al. 2012; Jah et al. 2004; Sen et al. 2009; Zandrino 
et al. 2000). If there is a focus elsewhere, BTB is termed secondary. The primary focus may 
be from the lung, lymph nodes including axillary, paratracheal and internal mammary nodes 
(2013; Halstead & Lecount 1898; Khanna et al. 2002; Mirsaeidi et al. 2007; Winzer et al. 
2005). BTB may also arise secondarily from haematogenous spread and from the contiguous 
spread of infection from adjacent organs such as chest wall, ribs and sternum (Winzer et al. 
2005). It is generally accepted that the lymphatic spread is by retrograde extension from the 
axillary nodes (Baharoon 2008; Domingo et al. 1990). This hypothesis has been supported 
by frequent unilateral ipsilateral axillary nodes involvement in 50-70% of tuberculous 
mastitis cases (Baharoon 2008).  
Old classification (McKeown & Wilkinson 
1952) 
New classification (Tewari & Shukla 2005) 
Nodular tubercular mastitis ( most common) Nodular-caseous tubercular mastitis 
 approx. (72%) 
Disseminated/ confluent tubercular mastitis Tubercular breast abscess approx. (26%) 
Sclerosing tubercular mastitis (mimics cancer, 
common in older women) 
Disseminated/confluent tubercular mastitis 
(approx. 2%) 
Tuberculous mastitis obliterans 
Acute miliary tubercular mastitis 
Table 1. 1 Classification of BTB 
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THE INCIDENCE AND PREVALENCE OF BTB 
As with other forms of TB, the incidence of BTB is dependent on the level of economic 
development of a country. In first world countries, the incidence of BTB is reported to be 
less than 0.1% of all surgically treated breast disease. On the other hand, developing 
countries have an incidence of approximately 3-4.5% among surgical breast cases (Kalaç et 
al. 2002). The high rate of HIV infections in developing countries further contributes to 
increasing the incidence of EPTB including BTB (Tewari & Shukla 2005; World Health 
Organisation. 2015). In a study done at Khuzestan Health Centre, Iran, where TB is 
considered endemic, only 9 BTB cases among 2235 patients with TB were found over a five 
year period from 2005-2009 (Shushtari et al. 2011). Other studies include those of Mehta et 
al. (2010), who reviewed 63 BTB cases among 5200 TB patients during the period 1992-
2008, whilst Tewari and Shukla (2005) reported 30 cases from a total of 1180 TB patients 
over a 20 year period. Makanjuola reported 6 cases identified among 1152 mammograms 
during a 3 year period in 1996 (Makanjuola et al. 1996). A summary of retrospective studies 
on BTB is provided in Table 1.2.  
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Study Country Number of  BTB 
cases 
Period of review 
Hiremath and Subramaniam (2015) India 7 2012-2014 
Tandon et al. (2014) Not available 22 Not available 
Khodabakhshi and Mehravar 
(2014) 
Iran 22 2002-2012 
Meerkotter et al. (2011) South Africa 21 2002-2008 
(2013); Shushtari et al. (2011) Iran 9 
(Total TB 2235) 
2005-2009 
Mehta et al. (2010) India 63 
1 male 
(Total TB 5200) 
1992-2008 
Afridi et al. (2009) India 30 1999-2007 
Da Silva et al. (2009) Brazil 20 1994-2007 
Atamanalp et al. (2010) Turkey 7 1988-2007 
Harris et al. (2006) India 38 
(1 male) 
1998-2003 
Ben Hassouna et al. (2005) Tunisia 65 1980-2001 
Tewari and Shukla (2005) India 30 
(Total TB 1180) 
1983-2003 
Bani-Hani et al. (2005) Jordan 9 1994-2003 
Sakr et al. (2004) Egypt 10 1999-2001 
Khanna et al. (2002) India 52 1986-2000 
Al-Marri et al. (2000) Qatar 13 1988-1998 
Oh et al. (1998) China 17 1983-1995 
Makanjuola et al. (1996) Saudi Arabia 6 
(Total 
mammograms 
1152) 
3 year period 
(no date) 
Table 1.2 Retrospective studies of BTB since 1995. Where the total TB population from 
which the BTB cases are drawn is reported, is listed here. 
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RISK FACTORS FOR THE DEVELOPMENT OF BTB 
Reported risk factors include multiparity (Al-Marri et al. 2000); lactation (Harris et al. 2006; 
Kalaç et al. 2002) and HIV (Hartstein & Leaf 1992). Age of onset varies widely, including 
adolescence (Indumathi et al. 2007), young adult (Afridi et al. 2009) and the elderly (Da 
Silva et al. 2009; Maroulis et al. 2008). BTB has occasionally been reported in male patients 
(Mehta et al. 2010; Rajagopala & Agarwal 2008). 
DIAGNOSIS OF BTB 
Diagnosis may be based on clinical breast examination, radiological tests and pathological 
investigations. The clinical appearance of an irregular mass associated with axillary 
lymphadenopathy is similar to breast cancer presentation, while the mammographic 
appearance of an irregular dense mass with enlarged dense axillary nodes mimic breast 
cancer is often provisionally reported by the radiologist as cancer. The lack of specific 
clinical and radiological appearances compounds the problem of misdiagnosis (Ben 
Hassouna et al. 2005). Early diagnosis and efficient distinction between BTB and breast 
cancer (BCA) is imperative, especially because BTB is a treatable condition.  
Clinical appearances 
A wide range of the breast symptoms and signs have been described. These include lump or 
mass, breast swelling, fluctuating mass, breast pain, nipple discharge, axillary lymph nodes, 
discharging sinuses, ulcers, cutaneous fistulae, fibrotic changes with breast atrophy and 
breast deformities (Makanjuola et al. 1996; Tewari & Shukla 2005). Constitutional 
symptoms are not common, except in patients who also have PTB (Mehta et al. 2010). 
Because constitutional symptoms such as fever are not always present, differentiation from 
cancer is not always possible when using clinical findings alone. In a recent study of six 
cases, symptoms included loss of weight and appetite, pain, weakness and fever. The fever 
was present in only two patients (Gill et al. 2012). The signs are nonspecific, can be insidious 
and often mimic those of BCA (Akcay et al. 2007; Bani-Hani et al. 2005; Farrokh et al. 
2010; Gill et al. 2012; Kapan et al. 2010; Maroulis et al. 2008; Woyke et al. 1980) and 
pyogenic breast abscess (Al-Roomi et al. 2009; Chauhan et al. 2006; Mathur 2009). 
Furthermore, BTB can co-exist with BCA (Akbulut et al. 2011). During an extensive 
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literature review, Akbulut et al found twenty nine cases of co-existing BTB and BCA from 
1899 to 2011 (Akbulut et al. 2011); with the inclusion of their own case report, there were 
thirty cases altogether.  
Pathological diagnosis 
Pathological methods in current use include fine needle aspiration cytology (FNAC) (Sriram 
et al. 2008), wide bore core biopsy/histopathology (Gupta et al. 2012), smear acid fast bacilli 
(AFB) on Ziehl-Neelsen (ZN) stain (Harris et al. 2006), TB culture (Deepa et al. 2011), 
polymerase chain reaction (PCR) (Chia BS 2012), QuantiFERON gold test for TB (Mazurek 
et al. 2005), interferon release assay (Sen et al. 2009), and incision/excision biopsy (Tewari 
& Shukla 2005). 
Fine needle aspiration cytology (FNAC)  
Although aspiration cytology cannot determine the etiological agent, the presence of 
epithelioid cell granulomas and necrosis is considered adequate for diagnosis, often allowing 
a diagnosis in up to 73% of cases (Sriram et al. 2008). However, the absence of necrosis on 
FNAC does not exclude BTB because of the small quantity of sample material, and FNAC 
is therefore of limited value (Akcay et al. 2007).  
Wide bore core biopsy/histopathology  
Core biopsy yields an adequately sized sample, and often yields a positive diagnosis (Tewari 
& Shukla 2005). The diagnosis is readily established by the presence of caseating granuloma, 
epithelioid cells, Langhans’ type giant cells and lympho-histiocytic aggregates (Harris et al. 
2006; Khanna et al. 2002). Gupta et al. (2012) have stressed the importance of always 
performing a tissue biopsy even in cases where the clinical impression is of a non-TB breast 
abscess  
Smear acid fast bacilli (AFB) on Ziehl-Neelsen (ZN) stain  
Abscess fluid and nipple discharge should be subjected to microscopy using ZN stain and 
AFB sought. The yield has been low, with Harris et al. (2006) reporting a 2% rate of positive 
ZN smears for AFB. The low number of bacilli in EPTB further complicates the diagnosis, 
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since 1,000 to 10,000 mycobacterium per gram of tissue are required in order to obtain a 
positive smear (Mathur 2009). Nor is an AFB-positive smear always adequate evidence for 
a definitive diagnosis of M. tuberculosis, as it should be differentiated from other 
mycobacterium species (Akcay et al. 2007).. 
TB culture (FNA and core biopsy): detection of m tuberculosis 
Detection of M. tuberculosis by culture takes time, and there is a significant possibility of 
false negative results, with some authors reporting a 50% false negative rate in samples with 
low mycobacterial counts. In a series of 14 cases, Deepa et al. (2011) showed the presence 
of acid-fast bacteria in 5 of 9 patients with a tuberculous breast. 
Furthermore, not all Mycobacteria are Mycobacterium tuberculosis (MTB). One case of 
atypical Mycobacterium causing breast infection has been reported (Verfaillie et al. 2004). 
This was an 85 year old man in whom FNAC of a breast mass revealed AFB and culture 
yielded Mycobacterium kansasii (Verfaillie et al. 2004). In another unusual case, bilateral 
BTB developed in a 25-year-old HIV-negative woman whilst she was on anti-tuberculous 
therapy (ATT) for PTB. She represented with fever, bilateral breast nodules and axillary 
lymphadenopathy. Breast ultrasound showed bilateral infective type lesion whilst FNAC 
demonstrated AFB. Culture revealed a mycobacterium complex consisting of 
Mycobacterium tuberculosis, Mycobacterium bovis, Mycobacterium africanum and 
Mycobacterium microti which were sensitive to second line ATT (Kaneria MV 2006).  
Polymerase chain reaction (PCR): (nucleic acid amplification tests/NAAT)  
PCR detects MTB. It is also beneficial in detecting mutations that give rise to drug resistance, 
and can identify multi drug resistant tuberculosis (MDR-TB) using Multiplex Allele-
Specific Polymerase Chain Reaction (MAS-PCR) (Chia BS 2012).  
Interferon release assays (IGRAs) 
Whole-blood enzyme-linked immunosorbent interferon release assays detect interferon 
secreted by T cells in response to antigens encoded in the region of difference 1 of MTB, a 
genomic segment from Bacillus Calmette-Guerin (BCG) and most environmental 
Mycobacteria. It has higher specificity than tuberculin skin test, and results are available 
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within 24hrs (Sen et al. 2009). The IGRAs which have been approved by the United States 
(U.S) Food and Drug Administration (FDA) are the QuantiFERON-TB Gold In-Tube test 
(QFT-GIT) and the T-SPOT.TB blood test (Oxford Immunotec Global PLC, Abingdon, 
England) (Centre for Disease Control and Prevention. 2014). 
Incision/Excision biopsy 
This is a more invasive procedure compared to core biopsy and FNAC and is hence reserved 
for cases where diagnosis cannot be achieved by either method. It can be done for a lump, 
ulcer, sinus or wall of an abscess cavity, whereby diagnosis is almost always confirmed 
(Tewari & Shukla 2005). Extreme care is required with histological interpretation as not all 
granulomas demonstrate necrosis. In a study of lymph-node granulomas, Khurram et al. 
(2007) found M. tuberculosis DNA in 50% of granulomas with necrosis, and in 50% of 
granulomas without necrosis  
DIFFERENTIAL DIAGNOSIS 
BCA and idiopathic granulomatous mastitis (IGM) are commonly included in the differential 
diagnosis of BTB, (Afridi et al. 2010; Baharoon 2008; Lacambra et al. 2011). There have 
been several reports of BTB mimicking BCA both clinically and radiologically (Akcay et al. 
2007; Farrokh et al. 2010; Gill et al. 2012; Goyal et al. 1998; Kant et al. 2008; Kapan et al. 
2010; Maroulis et al. 2008; Woyke et al. 1980). The distinction between TB mastitis and 
IGM is important because the treatment is different: ATT and steroid treatment respectively.   
The distinction between BTB and IGM is based on histological features because 
clinically the two conditions are not easily distinguishable. Predominantly neutrophilic 
inflammation with a lack of caseous necrosis favours IGM rather than TB (Akcay et al. 
2007). In cases where IGM was confused with cancer, the histopathologic association of 
benign ductolobular units that is seen with IGM can help to differentiate the two (Cheng et 
al. 2010). However, Baharoon recommends the addition of Mycobacterium Tuberculosis 
(MTB) PCR as part of routine investigation, because both ZN for AFB can be negative in 
FNAC, and histopathology may not demonstrate necrosis in cases of BTB (Baharoon 2008).  
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There are other causes of granulomatous lesions of the breast, and although they are not 
common, they should be considered and excluded before diagnosis of idiopathic lobular 
granulomatous mastitis is considered (Bakaris et al. 2006). Breast mass with discharging 
sinuses can occur in actinomycosis, with the presence of sulphur granules in the pus 
differentiating it from TB  (Akcay et al. 2007). Some cases have been confused with 
pyogenic abscesses, leading to delays in treatment (Al-Roomi et al. 2009; Chauhan et al. 
2006). Other differentials include fibroadenoma and fibrocystic change based on ultrasound 
appearances (Akcakaya et al. 2005). Radiological appearances can also be similar to 
traumatic fat necrosis, plasma cell mastitis and mammary dysplasia. Clinically and 
radiologically discharging sinuses can also be seen in other fungal infection such as 
blastomycosis (Da Silva et al. 2009). Histologically non caseating granulomas without 
draining sinuses can occur in sarcoidosis (Fiorucci et al. 2006). Granulomatous vasculitis, 
such as giant cell arteritis and Wegener's granulomatosis also need to be ruled out 
(McKendry & 1990). One confirmed case of Wegener’s granulomatosis of the breast was 
reported by (Veerysami et al. 2006). 
IMAGING OF BTB 
Following clinical examination, radiology is the first line of investigation for patients 
presenting with breast symptoms.  
Mammography (including Full Field Digital Mammography: FFDM) 
Mammography and ultrasound are the standard radiological modalities in use for breast 
diagnosis and for monitoring of disease and of treatment response (The Royal College of 
Radiologists 2013). Mammography was developed in 1960, and has been a recognised and 
established modality since 1969 (Gold 1992). By 1976 screening with mammography had 
become standard practice given its role in detecting early stage breast cancer (Moskowitz et 
al. 1976). 
Mammograms have been mainly used to define disease extent, but not to differentiate BTB 
from other differentials (Baharoon 2008). However, specific signs such as the skin bulge 
and sinus tract sign have been described (Makanjuola et al. 1996), this being  the result of 
contracted Cooper's ligament. Subsequent to this, Harris et al and Khanna provisionally 
12
diagnosed BTB on the basis of mammographic findings of skin thickening with sinus tracts, 
which were communicating with intramammary masses (Harris et al. 2006; Khanna et al. 
2002). Other mammographic appearances include irregular mass lesions, smooth well 
defined mass lesions, intramammary nodes, axillary nodes, asymmetric density, duct ectasia, 
skin thickening with nipple retraction, microcalcification and skin sinuses (Sakr et al. 2004). 
Some authors have termed the round mass appearance as pseudotumoral image, due to its 
lack of classic halo seen in benign lesions like fibroadenoma (del Agua et al. 2006). Non-
specific stromal thickening has also been found (Khanna et al. 2002). 
Mammography limitations reduced sensitivity for cancer detection in women with 
mammographically dense breasts (Kolb et al. 2002). Furthermore, the risk of radiation has 
resulted in guidelines restriction for mammograms to be performed in women above 35 years 
of age, with an exception being made for those younger patients who are classified as high 
risk (NHS Breast Screening Programme 2013). 
Digital Breast Tomosynthesis (DBT) 
In a recent study by Michell et al. (2012), the use of DBT additional to full field digital 
mammography (FFDM) and film-screen mammography combined, and film-screen 
mammography alone was found to increase the accuracy of breast lesion detection and 
characterisation. They screened 788 women.  The area under the curve (AUC) values showed 
significant increase in diagnostic accuracy with DBT addition to FFDM and film-screen 
mammography compared to FFDM plus film-screen mammography, and film screen 
mammography alone. The use of DBT has not been explored in the diagnosis of BTB. 
Another limitation is increased radiologist reading time per study (Dang et al. 2014).  
Ultrasound 
Patients below 35 years of age are investigated with ultrasound only, with an exception being 
made for those younger patients who are classified as high risk (NHS Breast Screening 
Programme 2013). The reason being to avoid exposure of young breast tissues to ionising 
radiation (Hendrick 2010). Mammography and ultrasound are both used in those over 35 
years of age. The appearances of BTB vary depending on the morphological subtype. 
Nodular caseous subtype appears as a hypoechoic mass, which may be irregular in outline, 
or be well defined. Diffuse subtype may appear as diffuse trabecular tissue thickening or 
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microcysts with oedema. The abscess subtype appears as a complex hypoechoic fluid 
collection, and may be connected to skin sinuses and fistulae (Kalaç et al. 2002). 
Ultrasound has a limitation of being operator dependent, which has the potential to increase 
imaging interpretation inter-observer variability  
Computed Tomography (CT scan)  
The value of CT scan needs to be further explored. No authors have extensively explored 
this valuable modern modality in evaluating breast infection. New multi-detector scanners 
with three-dimensional tube modulation together with adaptive x-ray shutters have led to 
significant dose reduction to the patients while improving image quality.  This is due to the 
use of optimized reconstruction algorithms (Rogalla P 2008).   
The cases described in the literature limited the use of CT scan  to evaluate the possibility of 
disease extension into the chest wall (Chalazonitis et al. 2003; Tewari & Shukla 2005). The 
other benefit of CT scan is that it can investigate the presence of pulmonary disease at the 
same time (Kalaç et al. 2002). CT scan machine make use of ionising radiation to generate 
images, it therefore has a relative contraindication in pregnant women. There are no 
dedicated mammo CT scanners in the market, hence it is currently not the modality of choice 
for breast related disorders.  
Magnetic Resonance Imaging scan (MRI)  
As with the CT scan, the usefulness of MRI needs to be explored. The literature indicated 
that it had mainly been used to identify TB outside breast, specifically in the thoracic wall 
(Chalazonitis et al. 2003; Tewari & Shukla 2005). One author used MRI to evaluate response 
to treatment in a patient with BTB. MRI before and after six months of ATT demonstrated 
full response (Fellah et al. 2006). In a study by Al-Khawari et al. (2011), ten patients who 
had granulomatous mastitis (GM) were evaluated by MRI. Final histology showed 
tuberculous mastitis in four patients, unknown aetiology GM in four and duct ectasia related 
GM in two patients. Because the MRI appearances were similar in all ten patients, they 
concluded that MRI could not differentiate BTB from GM (Al-Khawari et al. 2011). MRI is 
also useful in looking at the extent of disease spread beyond the breast. Both T1 weighted 
and T2 weighted MRI sequences are routinely acquired during MRI investigation. 
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Proton Magnetic Resonance Spectroscopy (MRS) 
This technique has proved useful in differentiating BTB from BCA in four cases where 
mammography, ultrasound and MRI indicated BCA rather than BTB. The absence of choline 
peak and the presence of strong lipid peak was suggestive of tuberculosis, which was later 
confirmed on  FNA (Popli et al. 2010). 
F-18 2-fluorodeoxy-D-glucose positron emission tomography (18F-FDG-PET-CT) scan 
Sathekge et al. (2012) conducted a prospective study to evaluate the use of 18F-FDG-PET 
CT in assessing response after 4 months of ATT in 20 patients with TB-HIV coinfection, 
specifically using lymph nodes (LN) parameters. They evaluated relationships between 
FDG-PET, CT and treatment outcome. They concluded that responding and nonresponding 
LNs could be differentiated using SUVmax cut off value of 4.5 and presence of at least one 
LN basin with peripheral rim enhancement and central low attenuation (PRECLO). 
However, in another study by the same author, it was found that dual phase 18 F-FDG-PET-
CT could not differentiate malignant lymph nodes from tuberculous nodes in 30 patients 
with solitary pulmonary nodule (Sathekge et al. 2010). 
Radiological diagnosis of BTB in the South African setting 
Despite the high incidence of TB in South Africa, there is little published information on the 
radiological appearance of BTB. Furthermore, all studies concerning the radiology of BTB 
in the last fifteen years have been retrospective due to the low incidence and prevalence of 
the disease. Meerkotter et al. (2011) conducted a retrospective chart review of 21 patients 
with BTB over a six year period from 2002–2008 in Johannesburg, recording presenting 
clinical, ultrasound and mammographic features. Their study was mainly descriptive and the 
statistics used was simple proportions with no reference to sensitivity or specificity. They 
described the appearances of BTB as nodular, disseminated and sclerosing types. This 
description differs from the most recent classification by Tewari and Shukla (2005), namely, 
nodular-caseous, disseminated/confluent and abscess varieties. Some important findings 
reported by Meerkotter included the presence of chest wall mass and ipsilateral axillary 
lymph nodes as the predominant presenting symptom. 
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Similarly Tewari and Shukla (2005) conducted a retrospective study of 30 BTB patients seen 
over a twenty year period (1983–2003), recording presenting features, pathological 
diagnosis and treatment  The authors did not determine sensitivity or specificity. There were 
30 cases out of a total of 1180, and they mention an incidence of 2.5%, although this appears 
like a 20-year period prevalence. 
MANAGEMENT OF BREAST TUBERCULOSIS 
Most patients respond to standard ATT. Early diagnosis and treatment of BTB may prevent 
debilitating complications including discharging sinuses and cutaneous fistulae, fibrosis 
and breast deformities (Bani-Hani et al. 2005; Sen et al. 2009). There is however little 
information in the literature regarding the morbidity and mortality rate. In TB endemic 
areas, patients presenting with a breast mass in whom histology showed granulomatous 
mastitis, should be candidates for ATT, even if culture results are negative for TB 
(Shushtari et al. 2011). The disadvantage of this empirical treatment is that IGM is 
treated with steroids, therefore patients who have IGM may not respond to ATT. The 
South African National TB guidelines recommend 6 months’ treatment for PTB whilst 
that for EPTB is 9 months (Department of Health (South Africa) 2014). Our local 
institution protocol is as follows.  
Initiation phase: 2 months 
• Rifafour (daily) 
o 38 – 54kg:    3 tablets 
o 55 – 70kg:    4 tablets 
o 71kg and above:  5 tablets 
• Pyridoxine (daily) 
o 25mg  
Maintenance phase: 7 months 
• Rifinah 150/75 (daily)    rifinah 300/150 (daily) 
o 38 – 54kg: 3 tablets    ≥ 55kg: 2 tablets 
• Pyridoxine (daily) 
o 25mg 
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Clinical response 
Follow up is monthly for the first two months to assess clinical response, followed by follow 
up every three months for the duration of the treatment. If there is no clinical response during 
the follow up visits, a repeat biopsy is performed, the sample obtained is sent for 
microbiology, culture and sensitivity to evaluate for drug resistance. 
Radiological response 
Mammography and breast ultrasound may be repeated if the referring clinician has concern. 
Although there are no documented criteria for radiological response, lack of reduction in 
size of lesion as well as lack of mammographic change in appearance may be indicative of 
non-response and possible drug resistance. Whereas most patients who presented with 
painful breast mass demonstrate a complete clinical and radiological response after six 
months of standard therapy (Akcay et al. 2007), there have been cases not responsive to 
standard treatment who may require surgical intervention (Shushtari et al. 2011). (Mehta et 
al. 2010) reviewed 63 cases and reported that only 18 cases (28%) responded to ATT alone. 
Over half the cases (55%) were complicated by the presence of sinuses, fistulae and 
deformities, requiring surgical intervention, typically by primary localised excision; one 
patient required a simple mastectomy.  
PROBLEM STATEMENT 
While BTB would appear to be uncommon, cases are likely to be encountered on a regular 
basis in developing countries such as South Africa subject to a higher background prevalence 
of TB. As shown in the foregoing literature review, literature on BTB is sparse, and in 
particular, information on its radiological appearances is lacking. Since the first line of 
investigation following clinical examination for most forms of breast disease is radiological 
imaging, there is a need for the radiology of BTB to be far better characterised. Though there 
is some information on mammography and ultrasound, very little is known about the 
appearances of BTB on the newer modalities of MRI and 18F-FDG-PET scanning. 
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AIM OF THE STUDY 
The aim of this study was to report our experience with BTB in Durban, South Africa, to 
assess the incidence of BTB as a proportion of all women attending the main referral clinics 
for breast disease, to study the appearances of BTB on MRI and PET-CT and to investigate 
their role in diagnosis and in the monitoring of response to ATT. 
OBJECTIVES 
The study had the following objectives: 
1. To assess the prevalence of BTB amongst patients attending the major surgical 
breast referral clinics in Durban, South Africa. 
2. To describe the clinical and radiological findings in patients with BTB, including 
an evaluation of current treatment methods. 
3. To describe the appearances of BTB on 18F-FDG-PET-CT and to study its potential 
utility in the assessment of treatment response. 
4. To describe the appearances of BTB on MRI and to study its potential utility in the 
assessment of treatment response. 
5. To explore the role of 18F-FDG-PET-CT as a non-invasive assessment method to 
differentiate BTB from BCA.  
6. To evaluate the value of diffusion weighted imaging (DWI), T2 Weighted (T2W) 
and dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) in 
differentiating BCA from BTB. 
7. To compare the values of breast lesion volume as measured by DCE-MRI and 
prone 18F-FDG-PET-CT imaging.  
Study design and methodology  
The study settings were at the Addington, King Edward and Inkosi Albert Luthuli Central 
Hospitals (IALCH) breast clinics, Durban, South Africa. The work is reported as seven sub-
studies, using a selection of methodologies appropriate to each, which are fully described in 
Chapters 2-7. 
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Subjects 
The BTB patient cohort studied in Chapter 2 here were not analysed for any subsequent 
study. The same cohort of BTB patients were studied in Chapters 3-7. Different groups of 
patients with BCA were studied in chapters 5-7. There is no overlap. 
STRUCTURE OF THE THESIS 
Chapter 1 
Introduction, literature review, aim, objectives and outline of methodology. 
Chapter 2 
Prevalence of breast tuberculosis: Retrospective analysis of 65 patients attending a tertiary 
hospital in Durban, South Africa. 
This chapter presents the literature review, methodology, results and discussion for 
Objectives 1 and 2, specifically determination of the prevalence of BTB, a description of the 
clinical and radiological patterns observed in these patients and the outcome of therapy. 
This was published as: Ramaema DP, Buccimazza I, Hift RJ. Prevalence of breast 
tuberculosis: Retrospective analysis of 65 patients attending a tertiary hospital in Durban, 
South Africa. S. Afr. Med. J. 2015; 105: 866-9. 
Chapter 3 
The role of 18F-FDG-PET-CT in breast tuberculosis: Patterns and assessment of response 
to treatment. 
This chapter presents the literature review, methodology, results and discussion for 
Objective 3, a description of the appearances of BTB on 18F-FDG-PET-CT and a preliminary 
study of its potential utility in the assessment of treatment response. 
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The work is presented in manuscript form as: Ramaema DP, Hift RJ, Somers S, Soni N. The 
role of 18F-FDG-PET-CT in breast tuberculosis: Patterns and assessment of response to 
treatment. 
Chapter 4 
The role of multiparametric MRI in breast tuberculosis: Morphological appearances and 
the evaluation of treatment response. 
This chapter presents the literature review, methodology, results and discussion for 
Objective 4, a description of the appearances of BTB on MRI and a preliminary study of its 
potential utility in the assessment of treatment response. 
The work is presented in manuscript form as: Ramaema DP, Hift RJ. The role of 
multiparametric MRI in breast tuberculosis: Morphological appearances and the evaluation 
of treatment response. 
Chapter 5 
Utility of 18F-FDG-PET-CT in differentiating breast cancer from breast tuberculosis. 
This chapter presents the literature review, methodology, results and discussion for 
Objective 5, an exploration of the role of 18F-FDG-PET-CT as a non-invasive assessment 
method to differentiate BTB from BCA. 
The work is presented in manuscript form as: Ramaema DP, Hift RJ. Utility of 18F-FDG-
PET-CT in differentiating breast cancer from breast tuberculosis. 
Chapter 6 
Differentiation of breast tuberculosis and breast cancer using diffusion-weighted, T2W and 
dynamic contrast-enhanced MRI.  
This chapter presents the literature review, methodology, results and discussion for 
Objective 6, an evaluation of the value of diffusion weighted imaging (DWI), T2W and 
DCE-MRI in differentiating BCA from BTB. 
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The work is presented in manuscript form as: Ramaema DP, Hift RJ. Differentiation of breast 
tuberculosis and breast cancer using diffusion-weighted, T2W and dynamic contrast-
enhanced MRI.  
Chapter 7 
Comparative study of breast lesion size evaluation using DCE-MRI at 1.5T and 18F-FDG- 
PET-CT in seven patients with breast tuberculosis or breast cancer. 
This chapter presents the literature review, methodology, results and discussion for 
Objective 7, a comparison of the values of breast lesion volume as measured by dynamic 
contrast-enhanced breast MRI (DCE-MRI) and prone 18F-FDG-PET-CT imaging.  
The work is presented in manuscript form as: Ramaema DP, Hift RJ. Comparative study of 
breast lesion size evaluation using DCE-MRI at 1.5T and 18F-FDG-PET-CT. 
Chapter 8 
Synthesis and discussion 
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It is estimated that over 1 billion people worldwide 
have tuberculosis (TB).[1] However, breast tuber­
culosis (BTB) is a rare condition. The incidence has 
been reported as <0.1% of all surgical breast lesions 
seen in developed countries and 3 ­ 4.5% of breast 
lesions in countries where BTB is endemic,[2,3] although even in 
this setting, carcinoma is far more commonly encountered.[4] While 
BTB is considered a manifestation of extrapulmonary tuberculosis 
(EPTB), it represents only about 0.1% of the disease burden of EPTB. 
However, there has been a resurgence of EPTB as a result of HIV, with 
estimated incidences as high as 50% in countries where HIV infection 
is endemic.[5]
The right and left breasts are equally affected by BTB, which 
may be bilateral in ~3% of cases.[6] Up to 70% of patients may have 
associated axillary lymphadenopathy, often with visible axillary 
swelling.[7] Constitutional symptoms are unusual in the absence of 
systemic and particularly pulmonary TB.[4]
No clinical or radiological features are absolutely diagnostic of 
BTB. The diagnosis is usually readily confirmed by biopsy with 
histological examination or fine­needle aspiration and staining 
for acid­fast bacilli (AFB), mycobacterial culture or polymerase 
chain reaction (PCR) testing. While the main differential diagnosis 
is carcinoma, other considerations are idiopathic granulomatous 
mastitis and fungal infections. Most patients respond to standard anti­
TB therapy (ATT).[8] It has been suggested that patients in endemic 
areas who have a breast mass with granulomatous inflammation on 
histological examination should receive ATT, even if culture results 
are negative for TB.[9] There have been reports that sinuses, fistulas 
and deformities may occasionally require primary localised excision 
or simple mastectomy, but this is not standard care.[4]
Objectives
To identify the various radiological patterns of BTB, and to assess 
available treatment options and response to treatment.
Methods
We identified 64 patients with a histological or cytological confirmed 
diagnosis of BTB. One patient with discharging axillary nodes and 
breast oedema was included even though cytological findings were 
not confirmatory; 65 patients were therefore included in the data 
analysis. Patients were diagnosed between 2000 and 2013. Data were 
collected from Addington (n=60 patients) and King Edward VIII 
hospitals (n=5), Durban, South Africa. The study was approved by 
the Bioethics Research Committee at the University of KwaZulu­
Natal, Durban (Reference No. BF213/13). A retrospective chart and 
radiology review focused on demographic, clinical, mammographic 
and ultrasound patterns and diagnostic and treatment methods.
Mammograms (mediolateral oblique (MLO) and craniocaudal 
views) were done using a standard Mecatronica analogue 
mammo graphic unit (± digital processing). Ultrasound images 
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Background. Breast tuberculosis (BTB) is uncommon, but not rare. Knowledge of the ways in which it can present can prevent unnecessary 
invasive procedures and delay in diagnosis. 
Objectives. To describe the clinical and radiological findings in patients with BTB, including evaluation of current treatment methods.
Methods. We retrospectively analysed 65 patients diagnosed with BTB at Addington and King Edward VIII hospitals, Durban, South 
Africa, between 2000 and 2013. Demographic, clinical and radiological findings and treatment outcomes were noted.
Results. A total of 11 092 patients underwent breast investigations between 2009 and 2013, with a prevalence of BTB for the period of 0.3% 
(30 patients). Of the 65 patients diagnosed between 2000 and 2013, 64 were female (98.5%) and one was male (1.5%). The age range was 23 ­ 
69 years (mean 38.5). The most common mammographic pattern was density (39.4%) and the least common a mass (6.1%). Isolated axillary 
lymphadenitis was found in 12.1%. Abscess was the commonest ultrasound pattern (39.0%). Of the 47 patients with a known history of 
pulmonary tuberculosis (TB), 68.1% (n=32) did not have radiological evidence of previous or concurrent pulmonary TB, nor was there 
evidence of TB elsewhere. Of 47 patients with known HIV status, 34 were HIV­positive. Fine­needle aspiration cytology had sensitivity of 
only 28% compared with 94% for histology. Of those treated, 72.7% obtained full resolution following 9 months of TB treatment; 25.0% did 
not complete treatment, and 2.3% (n=1) died while on treatment. Follow­up data on relapse rates after treatment completion and disease 
resolution are scanty.
Conclusion. Understanding and being aware of the various presentations of BTB make it possible to treat most patients successfully.
S Afr Med J 2015;105(10):866­869. DOI:10.7196/SAMJnew.7704
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were obtained on the various standard 
units using a 7.5 ­ 12.5 MHz linear 
probe. Mammographic patterns were 
classified as follows: asymmetrical density, 
asymmetrical density with axillary nodes, 
inflammation with axillary nodes, mass, 
mass with axillary nodes, nodes only, and 
normal. Ultrasound patterns were classified 
as abscess, abscess with axillary nodes, 
mass, mass with axillary nodes, oedema, 
oedema with nodes, thickening, nodes only, 
and normal.
Histological and microbiological diag­
nosis was done by obtaining core biopsy 
samples using a 14­gauge needle. Cytological 
diagnosis was done by FNA biopsy. Lesion 
localisation was either achieved by palpation 
or ultrasound guided.
Descriptive statistics using proportions 
were used to analyse results.
Results
Sixty­four records of patients with 
pathology­proven BTB and one with strong 
clinical but inconclusive cytological findings 
were identified during the period 2000 ­ 
2013. Accurate clinic attendance records 
were available for the years 2009 ­ 2013, and 
during this 5­year period a total of 11  092 
patients underwent breast investigations and 
30 were diagnosed with BTB (prevalence 
for the period 0.3%). Demographics and 
clinical presentation are described in Table 1. 
The age range was 23 ­ 69 years (mean 38.5 
years). Of the 65 patients, 26 presented with 
an inflammatory mass or disseminated form 
of BTB. Other associated clinical features are 
set out in Table 2. Of the 65 patients, only 
one was lactating. HIV status was known in 
47 patients, of whom 34 were HIV­positive. 
While 47 patients had a history of previous 
pulmonary TB, only 15 had radiological 
evidence of either previous or concurrent 
pulmonary TB.
Radiological features on mammograms 
and ultrasound scans are summarised in 
Fig. 1 (a and b, respectively). Of the 33 
patients who had mammograms, 16 demon­
strated ipsilateral or bilateral axillary 
lymphadenopathy. A density pattern was 
seen in 13 cases. Ultrasound scans were done 
in 41 patients. The commonest pattern was 
that of an abscess (16 cases, 39.0%).
Sensitivity for fine­needle aspiration 
cytology (FNAC) was 28% as opposed to 
94% for histology. AFB were seen in 10.3% 
of the FNAC specimens and 29.7% of the 
histology specimens. Of the 65 patients, 
59 received medical treatment, 3 received 
surgical intervention, and 3 were lost to 
follow­up after diagnosis. Of those who 
were treated, 72.7% obtained full resolution, 
25.0% did not complete treatment, and 2.3% 
died (n=1).
Discussion
Clinical and radiological findings
Inflammatory/disseminated
This pattern was the most common clinical 
presentation of BTB. However, among patients 
who had mammograms, this pattern was 
seen in 21.2% (Fig. 2, a). The mammogram 
typically demonstrated nonspecific diffuse 
stromal thickening. We noted that all cases 
with an inflammatory/disseminated form also 
Table 1. Demographic and clinical 
features (N=65)
Characteristics
Gender, n (%)
Female 64 (98.5)
Male 1 (1.5)
Age at presentation (years)
Range 23 ­ 69
Mean (SD) 38.5 (10.3)
Side, n (%)
Left 30 (46.2)
Right 33 (50.8)
Unknown 2 (3.1)
Axillary nodes, n (%)
Yes 21 (33.9)
No 41 (66.1)
Clinical presentation, n (%)
Abscess 2 (3.1)
Adenitis + oedema 16 (24.6)
Mass (nodular) form 17 (26.2)
 Inflammatory mass 
(disseminated)
26 (40.0)
Occult mass 1 (1.5)
Unknown 3 (4.6)
SD = standard deviation.
Table 2. Associated clinical features
Characteristics n (%)
History of pulmonary TB 
(N=47)
CXR normal 32 (49.2)
CXR abnormal 15 (23.1)
Pregnant/lactating assessed 
(N=65)
No 64 (98.5)
Yes 1 (1.5)
HIV status (N=47)
Negative 12 (18.5)
Positive 34 (52.3)
Refused testing 1 (1.5)
CXR = chest radiograph.
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Fig. 1. (a) Of 33 patients who had mammograms, 16 demonstrated ipsilateral or bilateral axillary lymphadenopathy. An asymmetrical density pattern was 
seen in 13 cases. (b) Ultrasound scans were performed in 41 patients. The commonest pattern was an abscess variety in (16 cases, 39%).
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had nodes. This supports the hypothesis that this form may be due to 
either reactive oedema or retrograde spread from the axillary lymph 
nodes.[10] To date, no study has specifically determined whether AFB 
are present in the oedematous or diffusely inflamed breast. Because of 
the appearances, it has been suggested that this in fact represents the 
clinical spectrum from inflammatory mass/disseminated to oedema. The 
major differential diagnosis of this form is inflammatory breast cancer. 
However, the combination of an inflammatory breast lesion and sinuses 
or fistulas favours BTB rather than cancer.[3] On the ultrasound scan, some 
disseminated forms appeared as diffuse trabecular thickening and oedema 
(Fig. 2, c), whereas others demonstrated a diffuse inflammatory mass.
Oedema with adenitis
The clinical presentation of oedema was noted in 24.6% of cases, 
and an ultrasound pattern of oedema was seen in 26.9% (n=11). 
In contrast to the disseminated/inflammatory form, where all had 
associated axillary lymph nodes, seven patients in this group (17.1%) 
did not have associated lymphadenopathy. This pattern can be found 
in other forms of mastitis.
Abscess variety
Even though clinical evaluation classified an abscess variety of BTB 
in only 3.1%, this was the most common pattern on ultrasound, 
seen in 39.0% (n=18), with or without adenitis. Ultrasound scans 
demonstrated complex solid­cystic heterogeneous hypoechoic 
masses and fluid collections. In our study, asymmetrical density was 
the commonest mammographic pattern (39.4%, n=13) associated 
with this classification. Three patients only had ultrasound diagnosis. 
The differential diagnosis was a pyogenic abscess, and some of 
our patients had in fact received treatment with antibiotics; it was 
only after lack of response to this that the diagnosis of tubercular 
abscess was considered. It is therefore important to obtain samples 
specifically for TB analysis in all cases of non­lactational breast 
abscess, even if there is no history of TB elsewhere.
Nodular (focal mass)
Clinically this form of BTB presented as a focal mass. On the 
mammograms the focal mass opacities had variable outlines, some 
having smooth margins while others were irregular. Some were 
single mass lesions, and others were multiple (Fig. 3). This was 
the third most common mammographic pattern, seen in 18.2% of 
patients. On ultrasound this form appeared as a hypoechoic solid 
or heterogeneous mass with a variable outline ranging from well­
defined round to irregular. Lesion size based on ultrasound ranged 
from 0.9 cm to 6.1 cm. The differential diagnosis of this form can 
range from benign fibroadenoma to breast cancer, depending on the 
lesion character on imaging. We did not find microcalcification to be 
a feature in our study.
Tuberculous lymphadenitis
Although isolated lymphadenitis was not reported on clinical 
presentation, it was seen in 12.1% of mammograms (n=4) and 2.4% 
of ultrasound scans (n=1). Nodes were intramammary, axillary, or 
both. Clinically, large nodes can extend to the skin surface to form 
discharging sinuses (Fig. 4, a). The intramammary nodes appeared 
as well­defined round, dense masses on the mammogram. These can 
be confused with a breast mass when they are solitary. Radiological 
differentiation of tuberculous axillary nodes from metastatic nodes 
a b
c
Fig. 2. Inflammatory/disseminated BTB, images taken from various 
patients. (a) mammogram, MLO views. The right breast is enlarged. Diffuse 
stromal thickening and skin oedema is evident. (b) Photograph of the left 
breast, showing inflammation of the skin. (c) Ultrasound images showing 
diffuse trabecular thickening with oedema as hypoechoic bands in between 
hyperechoic fibrofatty tissue.
a b
Fig. 3. Nodular form of BTB. Mammogram, MLO views. (a) At presen-
tation – multiple rounded mass opacities in the right breast, and enlarged 
dense right axillary nodes. (b) After 4 months of treatment with ATT, one 
small round mass opacity remains in the upper part.
Fig. 4. Tuberculous lymphadenitis. (a) Left axilla, enlarged nodes discharging 
onto skin sinuses. (b) Ultrasound Doppler scan showing hilum vessel and 
thick cortex. (c) Ultrasound scan showing node with thick 7 mm cortex 
(callipers). (d) Breast MRI T1 post-contrast axial image. Right axillary 
lymph nodes have peripheral rim enhancement and central low signal 
(PRECLO).
a b
c d
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remains difficult. In our series, ultrasound scanning of axillary nodes 
demonstrated oval, hypoechoic solid masses with thick cortices and 
loss of normal fatty hilum (Fig. 4, b and c). This appearance cannot 
be differentiated from that of a malignant or metastatic lymph node. 
Post­contrast magnetic resonance imaging (MRI) showed peripheral 
enhancement with a central low signal (Fig. 4, d). Another author 
described nodes as having peripheral enhancement with central 
low attenuation (PRECLO) on positive emission tomography with 
fluorodeoxyglucose integrated with computed tomography (18F­FDG 
PET/CT).[11]
Pathological findings
We found FNAC to be only 28% sensitive, whereas the sensitivity of 
histopathology was 94%. Necrotising granulomatous inflammation 
was seen in histological specimens. In support of the literature, 
the yield of AFB in our study was low, being positive in 10.3% 
of cytology and 29.6% of histology specimens. In one case, AFB 
were detected histologically by PCR testing. Harris et al.[12] 
reported a 2% rate of positive Ziehl­Neelsen smears for AFB 
from tuberculous breast abscess fluid. Furthermore, an AFB­
positive smear is not always adequate for a definitive diagnosis 
of Mycobacterium tuberculosis, as it should be differentiated from 
other Mycobacterium species.
Treatment
Of the 65 patients, 59 received medical treatment comprising 9 
months of standard ATT, 3 received both medical and surgical 
intervention involving abscess drainage, and 3 were lost to follow­
up and were never treated following diagnosis. Of those who were 
treated, 72.7% obtained full clinical resolution, 25.0% did not 
complete treatment, and one patient died. Response to treatment 
was assessed by clinical examination and repeated radiological 
investigations (ultrasound, mammography or both). Although there 
are no documented criteria for radiological response, drug resistance 
may be suspected when lesions fail to reduce in size or change their 
appearance on ultrasound or mammography. Ultrasound is especially 
useful in monitoring the abscess form of BTB, to detect residual fluid 
collections. In single studies, both MRI[13] and 18F­FDG PET/CT[11] 
have shown promise as tools for monitoring response.
Risk factors
Our data demonstrate the varied spectrum of BTB presentation, 
both clinical and radiological, as well as good outcome with medical 
treatment. Furthermore, the study illustrates some association of 
BTB with HIV. Although most patients with BTB are females, male 
patients are occasionally affected. Our study supports this, with 
only one of 65 patients (1.5%) being male. The mean age of the 
patients in our study was 38.5 years, with a range of 23 ­ 69 years, 
demonstrating that BTB is not limited to females of reproductive 
age, as has been reported in the literature.[14] Several risk factors for 
BTB have been described, including lactation, multiparity and HIV/
AIDS.[12] We found only one patient (1.5%) to be lactating. HIV 
status was known in 47 of our patients, of whom 72.3% (n=34) were 
HIV­positive. Although HIV infection has been associated with an 
increased incidence of EPTB, BTB still remains rare. BTB has been 
classified as primary or secondary. Whereas most studies report that 
the primary form of BTB is rare,[9] we found the opposite. A history of 
pulmonary TB was obtained from 47 patients, of whom 68.1% (n=32) 
had a normal chest radiograph and no evidence of pulmonary or 
concurrent TB or of TB elsewhere in the body. This finding suggests 
that half of our cohort had the primary form of BTB.
Study limitations
Limitations due to the retrospective nature of the study include 
incomplete data on follow­up after treatment completion, even 
though patients were scheduled for further visits.
Conclusions
Our findings demonstrate the varied clinical and radiological 
presentations of BTB. Early diagnosis can lead to full response 
following treatment with standard ATT, resulting in avoidance of 
more invasive surgical treatment which can potentially cause breast 
disfigurement. Clinicians need to be aware of these patterns and to 
have a high index of suspicion in order to prevent misdiagnosis and 
inappropriate management.
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ABSTRACT 
Aim 
The purpose of our study was to describe the appearances of breast tuberculosis (BTB) 
on 18F-FDG-PET-CT and to study its potential utility in the assessment of treatment 
response. 
Methods 
Five patients who presented with pathologically proven BTB were studied. All 
underwent a non-contrast enhanced whole body 18F-FDG-PET-CT baseline scan within two 
weeks of diagnosis. A follow-up scan was performed approximately 4 months after initiation 
of anti-tuberculous treatment (ATT). We compared the imaging patterns on 18F-FDG-PET-
CT scan of the responders and non-responders.  
Results 
Two metabolic activity distribution patterns were identified. In the breast only pattern 
(n=1), the patient had activity localised to the breast. In the combined breast/lymphatic 
pattern (n=4), patients showed spread beyond the breast including enlarged 18F-FDG avid 
lymph nodes. Three of the five patients demonstrated a clinical response to ATT, whilst two 
were non-responsive at 4 months. The change in SUVmax between the two groups was not 
significant (p=0.08). However, by linear regression, the responders had a highly statistically 
significant decrease in the SUVmax values compared to this same change in the non-
responders from their baseline, (p<0.001). The proportional change in the maximum 
diameter (Dmax) between the responders and the non-responders was not significant, 
(p=0.08). The number of lymph nodes basins and 3-D volume did not differ significantly 
between the two groups (p=1.000).  
Conclusions 
Two metabolic activity distribution patterns of BTB on 18F-FDG-PET-CT, namely a breast 
only and a combined breast/lymphatic patterns were identified. The SUVmax and Dmax may 
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be useful markers for identifying patients with BTB with a suboptimal response to 
antituberculous therapy.  
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INTRODUCTION 
There has been a resurgence of extra-pulmonary tuberculosis (EPTB), precipitated by the 
increasing prevalence of Human Immune Deficiency-Acquired Immune Deficiency 
Syndrome (HIV-AIDS) [1]. EPTB is an AIDS-defining condition, [2, 3] and the risk of 
EPTB increases with decreasing CD4 counts [4, 5]. Breast tuberculosis (BTB) is rare. A 
study in India identified 30 BTB cases out of a total of 1180 breast lesions over a 20 year 
period [6]. Another study also in India found 63 BTB cases out of a total of 5200 breast cases 
over a 16 year period [7]. In a recent study in South Africa, 65 BTB cases out of a total of 
11092 patients attending breast clinic were identified over a 5 year period, with a BTB period 
prevalence of 0.3% in this cohort [8]. The role of (fluorine-18)-fluoro-2-deoxy-D-glucose 
(18F-FDG) positron emission tomography (PET) integrated with computed tomography (18F-
FDG-PET-CT) in oncology is well established [9-11], with other applications being 
neurology, infections and inflammation [12-15]. Some interest in its application in TB has 
been developed in the past decade [16-18]. TB infection elicits an inflammatory response in 
which the macrophages and neutrophils predominantly metabolise glucose, and this 
increased glucose metabolism is detected with 18F-FDG. The intensity of 18F-FDG uptake is 
proportional to the intensity of the inflammatory response [19]. There are studies that have 
investigated the role of 18F-FDG-PET-CT in monitoring treatment response in both 
pulmonary TB (PTB) [20-22] and EPTB patients [16, 22, 23]. Coleman et al demonstrated 
quantitative PET-CT imaging changes in the five patients infected with pulmonary 
extremely drug resistant (XDR) TB who had linezolid added to their treatment regimen, and 
found correlation between reduction in lesion 18F-FDG activity and therapeutic response 
[20]. We have not found a study which focused on the 18F-FDG-PET-CT findings in patients 
with BTB.  
Several diagnostic tools have been employed in the diagnosis and monitoring of treatment 
response in BTB, including clinical [24], histological assessment [25], mammography , 
ultrasonography [26] and magnetic resonance imaging (MRI) [27, 28]. There are no 
documented data on the radiological treatment monitoring with the use of mammography 
and ultrasound, however these two modalities are known to be non-specific, hence may not 
be reliable in measuring disease resolution [27, 29, 30]. To our knowledge, there has not 
been a reported study or case report that has specifically evaluated the usefulness of 18F-
FDG-PET-CT in diagnosing and evaluating the treatment response of BTB. The purpose of 
36
6
our study was to explore the role of 18F-FDG-PET-CT in the non-invasive assessment of 
BTB.  
PATIENTS AND METHODS 
Study design 
We conducted a non-randomized prospective observational study between January 2014 and 
January 2015. Ethical clearance was obtained from the institution Biomedical Research 
Ethics Committee (BREC) (Ref BF213/13). All participants provided written, informed 
consent.  
Patients 
Five patients who presented with BTB were recruited. All of them had pathologically proven 
tuberculosis. Four had conclusive histology from either the breast or the axillary lymph 
nodes. Of these three had concurrent pulmonary TB (PTB). One patient had proven 
pulmonary TB and had already received 8 weeks of anti-tuberculous treatment (ATT), which 
might have contributed to the histology being inconclusive. This patient had clinical and 
radiological features compatible with BTB, and continued to demonstrate response of both 
the breast and the axillary nodes. Therefore we are confident that the breast and axillary 
nodes were part of the TB spectrum. The remaining four patients were immediately initiated 
on first line ATT at the time of diagnosis confirmation. All patients reported compliance 
with ATT. 
Methods 
All patients had undergone screening investigations at the referring breast clinic, including 
ultrasonography, with or without mammograms depending on the patient’s age. Following 
histological confirmation of BTB, patients were invited for a baseline 18F-FDG-PET-CT 
scan, which was timed to allow the breast and axillary node biopsy sites to heal, thereby 
minimising biopsy-associated injury as a confounder.  
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The baseline scan was done within two weeks of commencement on ATT, and the follow-
up scan was done after 4 months, as recommended by the Centre for Disease Control and 
Prevention of TB Guidelines [31]. At the time of the follow up scan the patients’ response 
to treatment was evaluated on the following criteria: improvement or worsening symptoms 
including pain, enlargement or reduction of the breast lesion or axillary lymph nodes, 
requirement for surgical intervention to alleviate signs and symptoms. Pain threshold was 
divided into mild, moderate and severe.  
The patients were divided into two groups as responders and non-responders to first line 
ATT. Those who demonstrated reduction in the size of breast lesion or axillary nodes 
together with improvement of symptoms were classed as responders. The patients who had 
enlargement of breast lesion or axillary nodes with or without symptom worsening, and those 
who needed surgical intervention to alleviate signs and symptoms were classed as non-
responders.  
18F-FDG-PET-CT image acquisition: 
The patients fasted for at least 6 hours prior to intravenous administration of 18F-FDG. They 
received 4 MBq/kg body weight (range 192-261MBq, 5.17-7.05mCi). Glucose values were 
obtained before I.V. injection. The department protocol requires glucose level to not exceed 
11.1mmol/L/, in order to reduce the competition of high plasma glucose with 18F-FDG and 
a diversion of the latter into muscle with reduced uptake by the inflammatory cells. None of 
our patients had glucose levels higher than acceptable.  
A whole body PET-CT scan was performed using a PET-CT scanner (Siemens Biograph 16 
slice, Erlangen, Germany). The scan was timed to commence between 60 and 90 min post 
injection of 18F-FDG. The PET images were acquired for a maximum of 8 bed positions at 
3 minutes per field of view in the craniocaudal direction, starting at the vertex of the skull 
and ending at the mid-femur point. The images were acquired at a zoom of 1 and a matrix 
of 168 x 168. An iterative reconstruction using 2 iterations and 24 subsets was used for post-
acquisition image processing. 
A diagnostic non-contrasted CT scan was acquired in the craniocaudal direction with the 
following parameters: 4D CARE dose for 100mAs, 120 kVp and 5 mm slice thickness, pitch 
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of 0.75 for a scan time of 25s. A CT Image multiplanar reconstruction was obtained using a 
kernel of B31f, abdomen window, slice thickness of 4 mm and a recon increment of 2 mm. 
Combined 18F-FDG-PET-CT analysis 
All the images were interpreted by two experienced nuclear medicine physicians and one 
experienced radiologist. The nuclear medicine physicians were blinded to the patient’s 
clinical treatment response status during the follow-up scan, but the radiologist was not 
blinded and the images were read in consensus.  
18F-FDG-PET-CT Quantitative analysis  
True-D software with automatic multi-planar orthogonal display of the regions of interest 
(ROI) in axial, sagittal and coronal planes was used to analyse the fused PET-CT images. 3-
D ROI were drawn around 18F-FDG-avid areas, and the maximum standardised uptake value 
(SUVmax) of all the 18F-FDG-avid lesions were recorded: For this cohort, the most avid 
lesions were found to be either the axillary lymph nodes or the breast. The maximum 
diameter (Dmax) of the most avid lesion and the number of the 18F-FDG-avid lymph nodes 
basins were recorded. If there were many adjacent nodes in a basin, these were considered 
as one, and the SUVmax of the whole basin was taken. The CT images were analysed for 
bilateral whole breast 3-D volume. 
18F-FDG-PET-CT Morphological analysis of lesion and disease extent 
The breast morphological pattern was analysed according to the BTB classifications as; 
abscess, disseminated/inflammatory, mass and axillary lymphadenitis with breast oedema 
[8]. The axillary lymph nodes were assessed for the presence of matted necrotic nodes. The 
chest/lung was evaluated on lung and mediastinal windows, and the following parameters 
were recorded: lung nodules; lung consolidation; lung cavitation; pleural thickening; and 
pleural effusion. The presence of extra-pulmonary, extra-mammary and extra-nodal 
(EPEMEN) hypermetabolic foci, which included liver, spleen, bones, and subcutaneous soft 
tissues were recorded. Based on the visual analysis, we observed the two patterns: the breast 
pattern and the combined breast/ lymphatic pattern [32]. 
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Statistical analysis 
Data were entered into Epi-Info [33] and were subsequently transferred to STATA 
(StataCorp. 2015: Stata Statistical Software, Release 14 College Station, TX) for analysis. 
The patients were classified as responders and non-responders. Summary statistics were used 
to analyse the demographics, clinical and initial basic radiological investigations. Non-
parametric Wilcoxon rank-sum was used to compare the mean change in the SUVmax levels 
at the two time points for each participant, and the Mann-Whitney U tests were applied to 
assess differences in the mean SUVmax between the responders and non-responders. The 
linear regression model was used to determine the mean change in the SUVmax when a follow 
up was undertaken between the two groups. 1 sided Fisher exact test was used for the 
differences of the lymph nodes. Results were considered significant where p values<0.05.  
RESULTS 
All the patients were female, with an age range of 23 to 42 years, Table 1. 18F-FDG-PET-
CT scan quantitative findings are summarised in Table 2. 
18F-FDG-PET-CT lesions and disease extent of breast tuberculosis patients 
We identified two patterns of disease in patients with BTB. In the breast only pattern (n=1), 
the patient had predominant activity localised to the breast region. This patient responded to 
treatment. In the combined breast/lymphatic pattern (n=4), patients demonstrated a 
combination of localised breast and spread beyond the breast including lymph node activity. 
This group consisted of two responders and two non-responders. Two patients with the 
combined breast/lymphatic pattern were HIV-infected on anti-retroviral treatment 
(ART) and had moderately low CD4 counts (233 and 289 cells/mm3). None of the 
patients demonstrated the lung pattern as defined by Soussan et al. [32]   Three of the five 
patients were responsive to ATT, whilst two were non-responsive at 4 months of treatment 
with ATT. The patterns of disease encountered on PET-CT scan are described in more detail 
in Table 3. 
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18F-FDG-PET-CT markers of treatment response 
When the SUVmax for the two time points per patient is plotted, there is a clear pattern 
illustrating that the rate of increase is higher for the non-responders compared to the 
responders (Fig. 2). For the non-responders at baseline, the mean SUVmax was 7.97±2.43, 
(range 6.25-9.69), and at 4 months, the mean SUVmax had increased to 16.79±0.34, (range 
16.55-17.03). For the responders at M0, the mean SUVmax was 8.64±2.29, (range 6.93-
11.25), and at 4months, the mean SUVmax had declined to 6.63±4.24, (range 1.74-9.40).  
The difference in both the proportional and the absolute change in SUVmax between the two 
groups was not significant, (p=0.08) (Fig. 1). On linear regression, responders had a 
significant decrease (mean relative decrease of 10.84) in their SUV compared to the change 
in the non-responders in relation to their baseline value (p<0.001).  
Similarly, the proportional change in the Dmax of the most avid lesion, for this cohort being 
either the breast or the axillary nodes, between the responders and the non-responders was 
not significant, (p=0.08) (Fig. 3). The number of lymph nodes basins was found not to differ 
significantly between the two groups (p=1.000). Similarly, the whole breast 3-D volume as 
measured on CT images did not differ between the responders and the non-responders 
(p=1.000). 
A total of 10 EPEMEN hypermetabolic foci were observed in the two non-responders, and 
not in the other patients. Both non-responders were HIV-TB co-infected. The foci in 
patient 1 included liver, spleen, four areas of bone involvement and one subcutaneous tissue. 
The second patient (patient 2) demonstrated 3 EPEMEN foci involving subcutaneous soft 
tissues.  
The presence of matted nodes did not discriminate between the two groups. All patients were 
followed up until declared disease-free, the longest duration being 16 months (n=1), whilst 
others received 9 months of treatment and disease resolution was confirmed (n=4). One of 
the two patients classified as non-responders in our study was managed with surgical 
debridement of the axilla, whilst the second non-responder received a prolonged 16 months 
of supportive treatment in addition to the ATT due to the severity of the disseminated TB. 
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Fig. 4 and Fig 5 show the 18F-FDG-PET-CT images of patient 2 (non-responder) with 
combined breast/lymphatic pattern and patient 4 (responder) with breast only pattern, at two 
time points respectively.  
DISCUSSION 
In developing countries TB has high mortality in HIV infected individuals [1, 34, 35]. HIV-
infected patients are more susceptible to TB including EPTB and may present more severely 
[4]. Furthermore drug-resistant forms of TB with associated complications are increasing, 
especially in the context of HIV-TB co-infection [1]. Thus, it is critical to have these 
potentially life-threatening strains recognised early in order to switch the treatment from the 
first line tuberculostatics to the second or the third line treatment. The utility of 18F-FDG-
PET-CT in demonstrating a response to treatment in the early stage of pulmonary TB has 
been shown [36]. In this study we aimed to evaluate the potential use of 18F-FDG-PET-CT 
in monitoring treatment response in patients with BTB and to further evaluate the disease 
extent and identify patterns of organ involvement. 
18F-FDG-PET-CT patterns and extent of disease in patients with breast tuberculosis 
We identified two metabolic distribution patterns based on the combined analysis of CT 
and 18F-FDG-PET. The breast only pattern was observed when the 18F-FDG activity was 
localised to the breast region, with lack of strong uptake elsewhere and no evidence of 
pulmonary infection on CT. There was an association of this pattern with good response to 
treatment and a generally well patient. The combined breast/lymphatic pattern comprised a 
combination of breast disease with 18F-FDG avidity and additional significant extra-
mammary systemic uptake, which could include lymph nodes, bone, hepato-splenic and 
subcutaneous tissues. Although lung nodules were present, they did not conform in 
distribution and number to the pattern described by Soussan et al. [32]. This combined 
pattern was seen in patients who were generally unwell, with two demonstrating poor 
response to ATT at 4 months. There are limited data regarding the patterns of TB on 18F-
FDG-PET-CT, and our search revealed only three studies [23, 32, 37]. Both Soussan et al. 
[32] and Martinez et al. [23] studies studied the findings on 18F-FDG-PET-CT in two patients 
with PTB. They identified two patterns: the lung pattern and the lymphatic pattern, the 
former being related to predominant lung infection whilst the latter was more associated with 
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severe systemic disease. Mehta [37] evaluated patterns of systemic uptake of 18F-FDG-PET-
CT in eleven patients with ocular TB, and described two patterns: one with no detectable 
systemic uptake, and a second with detectable systemic uptake which they further 
subcategorised as chest only, disseminated and extrapulmonary only. Our study describes 
another pattern; the breast only pattern. 
18F-FDG-PET-CT in treatment monitoring of breast tuberculosis patients 
One of the two patients classified as non-responders in our study was managed with surgical 
debridement of the axilla, whilst the second non-responder received a prolonged 16 months 
of supportive treatment in addition to the ATT due to the severity of the disseminated TB. 
Neither of them received second line ATT and both were followed up until completion of 
treatment and disease resolution. Both non-responders were HIV-infected on ART, which is 
likely to have affected the severity of the disease. Thus, though a lack of response should 
always raise concern about the possible development of drug resistance, which would require 
a switch to second line ATT [38] , it appears that in our cases the slow response was due to 
the severity and extent of the disease rather than resistance.  
Although 18F-FDG uptake is not specific for TB, the change in the SUVmax from the baseline 
to the follow up scan has been shown to be a good indicator of evaluating response and 
resistance to first line ATT [16, 21]. Our study demonstrated a significant change in the 
SUVmax on 18F-FDG-PET-CT at different time points during ATT for each patient. It also 
showed that the intensity of 18F-FDG uptake by the most avid lesion at 4 months is 
significantly higher in the non-responders than in the responders. We suggest therefore that 
the SUVmax can be used as a disease marker for serial quantification of disease activity.  
The proportional change in the maximum diameter (Dmax) of the most avid lesion appears to 
have potential in monitoring the response to treatment, confirming the suggestion of  [39]. 
The difference in proportional change between responders and non-responders approached 
statistical significance. We found that the 3-D breast volume was not predictive in assessing 
clinical response. 
The number of lymph node basins did not differ significantly in this study, in contrast with 
the findings of  [21] who reported that a cut-off of 5 or more lymph node basins had 88% 
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sensitivity and 81% specificity for separating ATT responders from non-responders in 
patients with HIV-TB coinfection. 
The presence of EPEMEN hypermetabolic foci, which are part of the EPTB spectrum, 
appears to be a marker of severity. We observed EPEMEN uptake only in the non-responders 
who also had HIV-TB co-infection. Anatomically these foci included the liver, spleen, bone 
and subcutaneous tissues. The liver and splenic lesions in our patients consisted of multiple 
tiny hypermetabolic cysts consistent with military TB [40]. In contrast, local hepatic TB is 
associated with focal lesions which are usually greater than 2mm [41]. We are unaware of 
any study, prior to the current study, in which breast involvement was described as part of 
the spectrum of EPTB in which the use of 18F-FDG-PET-CT has been explored.  
Study limitations 
The small sample size is related to the low prevalence of BTB and the prospective study 
design.  
Conclusion 
Our study identified two distinct metabolic activity distribution patterns of BTB on 18F-
FDG-PET-CT which include a breast only pattern and a combined breast/lymphatic pattern. 
We have further shown that 18F-FDG-PET-CT at 4 months after initiation of treatment of 
breast TB may be useful in evaluating the response to treatment. The SUVmax and the Dmax 
may be useful biomarkers in BTB for separating patients who are likely to respond to the 
standard first line tuberculostatics from those who require more aggressive treatment 
interventions including surgical and prolonged ATT period.  
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FIGURE LEGENDS 
Figure 1 
Boxplots showing the absolute change of SUVmax values for the responders and the non-
responders.  
Figure 2 
The SUVmax for the two time points per patient demonstrating that the rate of increase is 
higher for the non-responders compared to the responders. Red=non-responders, 
Blue=responders.  
Figure 3 
Boxplots demonstrating the proportional change in the Dmax of the presenting lesion (breast 
or axillary nodes) between the responders and the non-responders. 
Figure 4 
18F-FDG-PET-CT scan of a non-responder (Patient 2): Combined Breast/Lymphatic pattern. 
Axial 18F-FDG-PET images at breast level (A and B). A) Baseline scan: Diffusely enlarged 
left breast, and multiple matted large 18F-FDG avid left axillary nodes. B) 4 month follow-
up scan: Two metabolically active subcutaneous nodules in the posterior chest wall were 
present. The activity in the left axillary nodes had increased. Corresponding coronal whole 
body fused 18F-FDG-PET-CT images (C and D). C) Baseline scan: Widespread nodal 
disease. D) 4 months follow up scan: Progressive left breast oedema and enlargement as well 
as increased intensity and size of left axillary nodes.  
Figure 5 
18F-FDG-PET-CT scan of a (Patient 4): Breast only pattern: Axial 18F-FDG-PET images at 
breast level (A and B). A) Baseline scan: showed an 8.7cm left breast mass with thick 
metabolically active rim and hypodense photopaenic necrotic centre, with deep extension 
into the chest where there was invasion of the intercostal muscle and the pleural space. B) 4 
51
21
month follow-up scan: showed a separation of the breast mass from the pleura. The left breast 
mass had lost the necrotic centre and now appeared as a uniform, and had separated from 
pleura. Size reduced to 3.9cm. Corresponding coronal whole body fused 18F-FDG-PET-CT 
images (C and D). C) Baseline scan: D) 4 months follow up scan.  
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TABLE 1 
Patient demographic, clinical, mammography and ultrasound features. ALBE= axillary lymphadenitis and breast oedema; BAbsc=Breast abscess. 
MAL= matted axillary lymphadenopathy. AL= axillary lymphadenopathy. FM= focal mass.  
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TABLE 2 
Quantitative data of breast tuberculosis patients on 18F-FDG-PET-CT. M0=Baseline at start of the treatment, M1=follow up scan after 4 months 
of ATT. EPEMEN: Extra-pulmonary extra-mammary extra-nodal hypermetabolic foci. *One new lymph node basin was present in the follow-up 
scan. # Coincidental MFU not considered as EPEMEN. 
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TABLE 3 
18F-FDG-PET-CT lesions and disease extent of breast tuberculosis patients. Lt: left, RT: right. 
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FIGURE 4 
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CHAPTER 4 
The role of multiparametric MRI in breast tuberculosis: Morphological 
appearances and the evaluation of treatment response. 
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ABSTRACT 
Aim 
The aim of this study was to describe the appearances of breast tuberculosis on MRI and to 
study its potential utility in the assessment of treatment response. 
Methods 
We included 6 consecutive patients with pathologically proven breast tuberculosis who 
underwent a contrast enhanced MRI scan within two weeks of diagnosis. The repeat scan 
was timed at 4 months after initiation of the anti-tuberculous treatment. The patients were 
classified as responders or non-responders. 
Results 
All the patients were female with an age range of 23-43 years. All the lesions were 
hypointense on the pre-contrast T1W. The responders had uniformly hyperintense lesions 
on the pre-contrast T2W, whilst the non-responders had mixed signal intensity lesions. The 
enhancement patterns of foci and rim were present in equal proportions in both groups. All 
the patients demonstrated rim enhancing axillary nodes. The enhancement distribution in 
both groups included diffuse, focal and multifocal patterns. The differences (delta) between 
the two time points at the baseline and the follow-up were determined for the three 
parameters, ADC, T2SI and the breast lesion maximum diameter (Dmax). The mean delta 
ADC and the mean Delta T2SI were not statistically significant between the responders and 
the non-responders (p=0.901) and (p=0.282) respectively. In contrast, the mean delta Dmax 
showed statistically significant differences between the responders and the non-responders 
(p=0.024).  
Conclusions 
Our results indicate that the lesion maximum diameter can be valuable in monitoring the 
response to treatment of patients with breast tuberculosis. Furthermore, the combination of 
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rim enhancing breast lesions and axillary nodes on DCE-MRI appear to favour breast 
tuberculosis rather than breast cancer as a diagnosis.  
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INTRODUCTION 
Breast tuberculosis (BTB) is an uncommon manifestation of extrapulmonary tuberculosis 
(EPTB) [1]. Because of the low prevalence of BTB, there have been few studies on the 
disease [2, 3]. BTB has been classified into five distinct patterns based on mammography 
and ultrasound findings: inflammatory/disseminated, oedema with adenitis, abscess, nodular 
and axillary tuberculous lymphadenitis [4]. Whilst the abscess pattern can readily point the 
physician to the possible diagnosis of an infective cause, other patterns are still easily 
confused with malignancy at presentation [5, 6]. 
The diagnosis of the disease has been achieved through the clinical, radiological and 
pathological assessment [7, 8]. Mammography and breast ultrasound scans are widely used 
radiological tests in all women who present with breast disease [9]. Confirmatory diagnosis 
is obtained from various pathological methods which may include histology, culture, fine 
needle aspiration cytology (FNAC), the interferon release assays tests [10, 11] and the 
nucleic acid amplification tests (NAATs) [12]. Newer tests which have proved particularly 
useful in EPTB diagnosis include the urinary lipoarabinomannan (LAM) for patients with 
CD4 counts less than 100/mm3 [13, 14]. The South African treatment guidelines for TB 
permit the discretionary extension of the standard 6 month-treatment regimen to 9 months 
or longer in the case of extrapulmonary tuberculosis, which is the protocol followed in our 
patients [15, 16].  
Response to treatment of BTB is currently monitored with a combination of clinical, 
mammography and ultrasound at scheduled return visits. Resistance to treatment may be 
suspected when there is no improvement in signs and symptoms [5]. To date, we could not 
find data of a study which specifically evaluated BTB response to treatment by radiological 
means. It is well documented that mammography features are not specific for BTB [17] 
hence identifying patients not responding to treatment may prove difficult with the use of 
this mammography alone.  
The use of magnetic resonance imaging (MRI) in treatment monitoring is well established 
in breast cancer management [18, 19], with some of the common indications being; for the 
pre-operative staging, in patients receiving neo-adjuvant chemotherapy at the baseline and 
70
5
the follow-ups to evaluate the efficacy of therapy [20, 21]. It is also used as a screening tool 
to monitor young patients with a strong family history [22].  
MRI has an established role in monitoring treatment response of EPTB involving the central 
nervous system (CNS) [23, 24], the musculoskeletal system (MSK) [25, 26] and abdominal 
TB [27]. We found one case report [28] which describes the use of MRI in evaluating 
response to treatment of BTB. The authors used contrast enhanced breast MRI in one patient 
to assess the resolution of BTB on completion of therapy, rather than for disease monitoring 
during treatment [28]. Comparison was made between the baseline and follow-up scan after 
six months of anti-tuberculous treatment (ATT), and complete radiological response was 
demonstrated [28]. Another study used magnetic resonance spectroscopy (MRS) in four 
patients with BTB but there was no follow-up to assess the response [29]. The technique was 
used to differentiate BTB from breast carcinoma (BCA) in four cases where mammography, 
ultrasound and MRI indicated breast cancer rather than TB. The absence of choline peak and 
the presence of strong lipid peak was suggestive of tuberculosis, which was later confirmed 
on FNAC[29].  
There is evidence that the breast morphological appearance on the dynamic contrast 
enhanced MRI (DCE-MRI) is an important characteristic for predicting the likelihood of 
malignancy [30]. There is paucity of literature on the appearances of BTB on DCE-MRI, we 
found only one study that was performed on 6 patients with BTB in 1998 [31]. The study 
evaluated a total of seven breast lesions, four of which demonstrated ring/rim enhancement, 
two had internal enhancement, and one lesion did not have any enhancement[31]. The 
purpose of our study was to determine the morphological patterns of BTB on 
multiparametric MRI, which includes T1W, T2W, DWI and DCE-MRI, as well as to use 
quantitative parameters to assess response to treatment. 
PATIENTS AND METHODS 
We recruited six consecutively identified patients with BTB who were newly diagnosed with 
BTB between January 2014 and January 2015. Ethical clearance was obtained from our 
institution’s Biomedical Research Ethics Committee (Reference number BF213/13). Five 
patients had conclusive histology either from the breast or the axillary lymph nodes. One 
patient had inconclusive histology from the breast and the axilla, but had microbiologically 
71
6
proven pulmonary TB for which she had received 8 weeks of ATT. Her clinical and 
radiological features were compatible with BTB and she continued to demonstrate positive 
response to treatment. All the participants provided written informed consent.  
All patients had undergone preliminary clinical and radiological investigations at the breast 
clinic. Following histological confirmation of BTB, the patients were invited for a baseline 
MRI scan. A follow up scan was performed approximately 4 four months after the initiation 
of ATT. One patient declined to have a follow-up MRI scan, however, she agreed to come 
for follow-up mammograms, therefore her treatment response was evaluated based on the 
clinical, mammographic and ultrasound results. Her results were evaluated in relation to the 
qualitative morphological features at start of treatment but not in the quantitative evaluation 
of treatment response. The patients were divided into two groups as either responders or 
non-responders at the time of their follow-up scan. Response was based on the following 
criteria: improvement in symptoms; reduction in size of the breast lesion and/or axillary 
lymph nodes; no requirement for surgical intervention for alleviation of symptoms.  
MRI imaging 
MRI was performed on a 1.5T machine (Siemens, Erlangen, Germany) using a dedicated 
breast coil. The patients were scanned in the prone position. Power injection of 20 ml 
intravenous (I.V) Magnevist® (Gadopentetate Dimeglumine, Bayer) Standard 469 
mg/mL (0.5 mmol/mL) at a dosage of 0.1 mmol/kg was administered to all the 
patients. The IV contrast rate was 3ml/sec followed by a 20 ml saline flush 
administered as a bolus. The T1 dynamic phase scan time was 6 minutes 41 seconds, 
during which 5 dynamic sequences were obtained in the axial position at various time 
points. The technical parameters are shown in Table 1.  
MRI image analysis 
All the images were read by one of the authors (DPR), an experienced breast radiologist with 
15 years of experience. There was no blinding to clinical information. The images were 
viewed and analysed on the Syngo-via post-processing workstation (Siemens, Erlangen, 
Germany). Where indicated, the region of interest (ROI) was placed around the lesion to 
cover the entire circumference.  
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The following quantitative parameters were measured for each patient: Apparent diffusion 
coefficient (ADC value), T2 signal intensity (T2SI) value and breast lesion maximum 
diameter (Dmax). Qualitative MRI characteristics used included the current Breast Imaging-
Reporting and Data System (BI-RADS) descriptors [32]. We recorded; the side; pre-contrast 
T1 and T2 signal intensity; breast lesion enhancement pattern; and axillary node 
enhancement pattern. Signal intensity was classed as hyperintense; isointense; hypointense; 
and mixed. The enhancement pattern was classified according to the three main BI-RADS 
descriptors as a) Focus or foci (<5mm); b) Mass and c) Non-mass enhancement (NME). The 
mass pattern internal enhancement characteristic was grouped as: i) solid-cystic; ii) rim; iii) 
homogeneous; and iv) heterogeneous; The axillary node enhancement pattern was classed 
as either ring/rim or homogeneous. The enhancement distribution was classified as a) 
diffuse; b) unifocal; and c) multifocal; all with or without chest wall involvement. 
Statistical analysis 
Data were entered into an Excel spreadsheet (Microsoft Excel 2013. Redmond, WA) and 
analysed using the STATA software package (StataCorp. 2015: Stata Statistical Software, 
Release 14. College Station, TX). Differences were evaluated with a two-tailed t-test. A p 
value of < 0.05 was considered significant.  
RESULTS 
Patient demographics and qualitative MRI features 
All the patients were female with an age range of 23-43 years. One patient, Patient 5, was 
studied at baseline only as she declined a follow-up study. She is known however to be a responder, 
since this was demonstrated on serial mammography. She has therefore been included as a responder, 
and the data available for her analysed accordingly. 
Four of these patients had right-sided involvement, and two left-sided. Four patients were 
identified as responders. Two patients were identified as non-responders due to reported 
increasing breast pain, visual breast and axillary nodes enlargement in both, and one required 
surgical intervention to debride the axillary tuberculous abscesses. Both non-responders 
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were HIV positive. Amongst the four responders, one was HIV positive, two HIV negative 
and one patient had an unknown status.  
The appearances of pre and post-contrast BTB lesions in a responder vs a non-responder are 
depicted in Fig. 1. All the lesions were hypointense on the pre-contrast T1 (Fig. 1a). All four 
responders had hyperintense lesions on pre-contrast T2 (Fig. 1b), whilst the two non-
responders had mixed signal intensity lesions (Fig. 1e). The observed enhancement patterns 
in the responders were NME (Fig. 2a) and mass: rim (Fig. 2b) in equal proportions. 
Similarly, these two patterns were observed in the non-responders in equal proportions. All 
patients demonstrated rim enhancing axillary nodes (Fig. 2c). The results are summarised in 
Table 2. 
Quantitative imaging features 
The differences (delta) between the two time points at the baseline and the follow-ups were 
determined for the three MRI parameters, ADC, T2SI and Dmax. Differences in the mean 
Delta ADC and the mean Delta T2SI did not differ statistically between the responders and 
the non-responders (p=0.901 and p=0.282 respectively). In contrast, the mean Delta Dmax 
showed a statistically significant difference between the responders and the non-responders 
(p=0.024). These results are summarised in Table 3 and 4. 
DISCUSSION 
The incidence of tuberculosis is rising and the disease remains a challenge in developing 
countries [33, 34].Treatment can be effective in most cases if the disease is diagnosed early 
[16], though the development of drug resistant strains has compounded the complication of 
managing patients with TB [34]. In this study we have demonstrated the variable 
morphological appearance of BTB when assessed on the DCE-MRI, and explored the 
potential biomarkers which may be utilised in treatment monitoring.  
Characteristics of breast TB on MRI 
All the lesions were hypointense on pre-contrast T1 weighted (T1W), whereas on pre-
contrast T2 weighted (T2W) all the responders had uniformly hyperintense lesions and the 
non-responders demonstrated mixed signal intensity lesions. None of the lesions were 
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uniformly hypointense on T2. This observation can play an important role in differentiating 
BTB from BCA because the majority of BCA are hypointense on T2 weighted imaging [35-
37]. There is limited literature on the appearances of BTB on DCE-MRI, we found only one 
study that was performed on 6 patients with BTB in 1998 [31]. The authors reported similar 
findings to our study, they had a total of seven breast lesions, all lesions were hypointense 
on pre-contrast T1W, however they did not mention T2W appearances [31]. 
It is important to note that other benign lesions such as cysts, lymph nodes and fibroadenoma 
are usually hyperintense on T2 [38]. However, cysts generally, do not enhance post-contrast 
unless they have a complex component [39]. Lymph nodes [40]and fibroadenomas [41] have 
their own distinct morphological appearances on other sequences and on post contrast 
imaging [36]. Following the administration of the I.V. contrast, the enhancement pattern was 
either NME or rim enhancing mass. None of the BTB lesions demonstrated solid-cystic, 
homogeneous or heterogeneous enhancing mass pattern. Again, this might be an important 
differentiating factor from BCA, especially if the breast cancer has cystic elements. The 
presence of solid elements in a cystic mass may favour breast cancer instead of BTB. Oh et 
al found four out of a total of seven BTB lesions demonstrated ring/rim enhancement, 
however in contrast to ours, two had internal enhancement, and one lesion did not have any 
enhancement [31]. The differences could be due to advancement in imaging techniques since 
1998.  
All the lymph nodes showed rim-enhancement with the central low signal consistent with 
typical necrotic nodes found in TB [27, 42]. The enhancement distribution ranged from 
diffuse, focal and multifocal with and without the chest wall involvement in both responders 
and non-responders and these patterns can all occur in breast cancer [32]. 
Changes in morphology and quantitative markers with treatment 
On the morphological analysis, whereas all BTB lesions were hypointense on pre-contrast 
T1W, all the responders had uniformly hyperintense lesions and the non-responders 
demonstrated mixed signal intensity lesions on pre-contrast T2 weighted (T2W) sequence. 
There is data regarding the use of breast MRI quantitative parameters in the evaluation of 
the response to cancer treatment, especially in patients receiving neoadjuvant chemotherapy 
(NAC) [43-45] . Hahn et al evaluated the role of DWI as an adjunct to DCE-MRI in 
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evaluating residual BCA following NAC. The investigators found that the accuracy for the 
detection of residual cancer improved with a combination of both modalities instead of each 
individual modality [44]. We have not found a study in which the ADC, the T2SI value or 
the Dmax were used to evaluate response to BTB treatment. In our study, we found that the 
Dmax is the best discriminator between the responders and the non-responders (p=0.024). 
The other two biomarkers, namely the ADC value and T2SI were not useful in differentiating 
the responders from the non-responders.  
Our preliminary results therefore suggest that the combination of the DCE-MRI 
morphological patterns and the Dmax may have a potential role in the diagnosis of breast 
tuberculosis, particularly in terms of differentiating it from breast cancer, and in the 
monitoring of response to treatment. 
There were several limitations to our study: Firstly, the small sample size reflects the low 
prevalence of BTB. Secondly, the images were read by one radiologist. Confirmation of 
these preliminary results will require a larger, multicentre study with formal assessment of 
inter-reader agreements.  
Conclusions 
Our results indicate that the lesion maximum diameter can be valuable in treatment 
monitoring in breast tuberculosis patients. Furthermore, the morphological features of T2W 
hyperintensity, DCE-MRI rim-enhancing breast lesions associated with ring/rim-
enhancing axillary nodes favour breast tuberculosis than breast cancer and may play a role 
in differentiating these two conditions.  
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FIGURE LEGENDS 
Figure 1 
(A-F): Axial pre-and post-contrast breast MRI images of two patients with breast 
tuberculosis (BTB), (A-C) a responder and (D-E) non-responder. a) Pre-contrast T1 
hypointense lesion in the left breast of a responder. b) Pre-contrast T2 hyperintense lesion 
in the left breast. c) Post-contrast T1 showing rim enhancing lesion. d) Pre-contrast T1 
hypointense lesions in the right breast of a non-responder. e) Pre-contrast T2 mixed signal 
intensity lesions in the right breast. f) Post-contrast lesions in the right breast of a non-
responder demonstrating multiple rim-enhancing lesions. 
Figure 2 
(A-C): Axial T1 post-contrast subtracted breast MRI images of various patients with breast 
tuberculosis (BTB). a) Non-mass enhancement (NME) pattern in the unilaterally enlarged 
left breast. b) Rim-enhancing breast lesions in the shrunken left breast. c) Rim-enhancing 
right axillary nodes.  
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TABLE 1 
Local dynamic contrast-enhanced breast MRI protocol technical parameters. TSE=Turbo Spin Echo; GE=Gradient Echo; STIR=Short Tau 
Inversion Recovery. 
MRI sequence Acquisition 
plane 
Repetition 
time (TR) 
(msec) 
Echo Time 
(TE) (msec) 
Inversion 
time (msec) 
Matrix size Field of 
view (FoV) 
(mm) 
Slice 
thickness 
(mm) 
Voxel size 
(mm) 
Localizer sagittal 7.6 3.53 - 384 x 512 400 6 2.1x1.6x6.0 
T1 precontrast GE 
3D  
axial 8.6 4.70 - 299 x 384 320 1 1.0x0.7x1.0 
T1 GE 3D dynamic 
sequences ( 1 pre& 
5post contrast)  
axial 9.1 4.76 - 299 x 284 340 1.5 1.1x0.9x1.5 
T1 3D Dixon axial 7.20 first 2.38; 
second 4.76 
- 320 x 320 340 1.8 1.1x1.1x1.8 
T1 fat sat axial 680 10 - 224 x 320 320 4 1.4x1.0x4.0 
T2 STIR axial 5600 59.0 170 314 x 320 340 4 1.1x1.1x4.0 
T2 TSE axial 6100 111 - 384 x 512 320 4 1.7x1.3x4.0 
DWI b values 0 & 
800s/mm2 
axial 9200 86 180 150 x 192 380 4 2.0x2.0x4.0 
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TABLE 2 
MRI qualitative characteristic of breast tuberculosis patients at the baseline scan. The 
descriptive categories employed are listed in the text under Methods. 
 
Characteristic Responder 
(n=4) 
Non 
responder 
(n=2) 
T1 (precontrast)   
Hyperintense   
Isointense   
Hypointense 4 2 
T2 (precontrast)   
Hyperintense 4  
Isointense   
Hypointense   
Mixed hyper/iso/hypointense  2 
Enhancement pattern   
Focus/Foci (<5mm)   
Non-mass enhancement-NME  2 1 
Mass:   
Solid-cystic   
Rim 2 1 
Homogeneous   
Heterogeneous   
Axillary nodes enhancement   
Rim 4 2 
Homogeneous   
Enhancement distribution   
Diffuse, and chest wall ext.   
Diffuse, No chest wall ext. 2 1 
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Characteristic Responder 
(n=4) 
Non 
responder 
(n=2) 
Focal, and chest wall ext.   
Focal, No chest wall ext. 1  
Multifocal, and chest wall ext.   
Multifocal, No chest wall ext 1 1 
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TABLE 3 
MRI quantitative parameters of breast tuberculosis patients.ADC-0, T2SI-0, Dmax-0: corresponding values at baseline. ADC-1, T2SI-1, Dmax-1: 
corresponding values at 4 month follow-up examination. Units are: ADC: x10-6mm2/sec); Dmax: cm. Patient 5, was studied at baseline only as 
she declined a follow-up study. She is known however to be a responder, since this was demonstrated on serial mammography. She has therefore 
been included as a responder, and the data available for her analysed accordingly. 
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Responder 
(yes/no) 
Patient HIV 
status 
ADC-0 
(n=6) 
Mean 
(SD) 
ADC-1 
(n=5) 
Mean 
(SD) 
Delta 
ADC 
(n=5) 
Mean 
(SD) 
T2SI-0 
(n=6) 
Mean 
(SD) 
T2SI-1 
(n-5) 
Mean 
(SD) 
Delta 
T2SI 
(n-5) 
Mean 
(SD) 
Dmax-0 Dmax-1 Delta 
(Dmax) 
No 1 pos 993.38 2084.36 -
1090.98 
790.2 379.63 410.57 3.9 3.9 0 
No 2 pos 1994.58 2168.03 -173.45 945.13 1074.11 -128.98 1.7 3.4 -1.7 
Yes 3 Not 
tested 
972.75 199.54 773.21 400.39 144.07 256.32 4.5 2.4 2.1 
Yes 4 pos 1558.79 1725.81 -167.02 863.47 753.12 110.35 8.9 7.1 1.8 
Yes 5 pos 2135.96 - - 857.09 - - 3 - - 
Yes 6 neg 2489.15 1293.32 1195.83 870.19 438.85 431.34 3 1.2 1.8 
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TABLE 4 
Delta Mean MRI parameter values between the responders and the non-responders patients with breast tuberculosis. 
 
MRI parameter Non-Responders (n=2) Responders (n=3) p value 
Delta ADC 
Mean ± SD (x10-6mm2/sec) 
-632.21 ± 648.79 
(95% CI,-6461.37-5196.94) 
600.67 ± 697.61 
(95% CI,-1132.29-2333.64) 
0.901 
Delta T2SI  
Mean ± SD 
140.79 ± 381.51 (95% CI,-
3287.02-3568.61) 
266.00 ± 160.71 (95% CI,-
133.23-665.23) 
0.282 
Delta Lesion diameter (Dmax)  
Mean ± SD (cm) 
-0.85 ± 1.2 (95% CI,-11.65-9.95) 1.90 ± 0.17 (95% CI, 1.46-2.33) 0.024 
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FIGURE 1 
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FIGURE 2 
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CHAPTER 5 
Utility of 18F-FDG-PET-CT in differentiating breast cancer from breast 
tuberculosis
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ABSTRACT 
Aim 
The purpose of our study was to explore the role of 18F-FDG-PET-CT as a non-invasive 
assessment method to differentiate breast tuberculosis (BTB) from breast cancer (BCA).  
Methods 
We reviewed 18F-FDG-PET-CT findings of twenty nine patients, 24 with BCA and 5 with 
BTB. The maximum standardised uptake value (SUVmax) and the CT density in Hounsfield 
units (HU) of the breast lesions and axillary nodes were measured. The demographics and 
pertinent PET-CT morphological appearances were recorded.  
Results 
All patients were female. The age of the patients with BTB ranged from 23 to 42 years, and 
of those with BCA from 34 to 76 years. The commonest morphological pattern for the cancer 
group was that of a mass, whereas for the BTB group there were equal proportions for the 
mass and oedema morphologies. The mean (SD) SUVmax of the breast lesions in the BCA 
patients were significantly higher than in those of the BTB patients, 12.59±8.11 vs 3.14±1.55 
(p=0.016). There was no statistically significant difference in the mean SUVmax of the 
axillary lymph nodes, the breast lesion density (HU) or the axillary lymph nodes density.  
Conclusions 
The SUVmax was useful for distinguishing the breast lesions in cancer and tuberculosis 
patients, but not for the axillary nodes. The Hounsfield density was not useful for 
differentiating either the breast lesions or the axillary nodes.  
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INTRODUCTION 
While breast cancer (BCA) is globally one of the commonest cancers in women [1], the 
incidence of breast tuberculosis (BTB) is low [2-4]. There is a significant overlap in the 
clinical presentation of the two conditions, creating the possibility for incorrect diagnosis 
[3]. This is complicated by the poor specificity of the currently available routine imaging 
modalities, including mammography and ultrasound, in distinguishing the two conditions 
[5].  
18F-FDG-PET-CT has established a role in managing advanced, recurrent and metastatic 
BCA [6], and there is emerging evidence regarding the use of this modality in early breast 
cancer [7, 8]. It has also been studied as a modality for differentiating pulmonary tuberculosis 
(PTB) from malignant conditions with varying results [9-11]. In recent years, there has been 
increasing evidence for the utility of 18F-FDG-PET-CT in diagnosing inflammatory and 
infective conditions [12-15]. In areas where TB is endemic, one study has found that 18F-
FDG-PET-CT was not useful to differentiate benign from malignant pulmonary nodule [16]. 
Similarly in another study performed in China where TB is endemic, the authors found 
lower specificity (61.1%) for 18F-FDG-PET due to the high percentage (57.14%) of false 
positives from TB. The specificity of CT was slightly higher than that of 18F-FDG-PET.  
The authors concluded that the combined 18F-FDG-PET-CT offered greater diagnostic 
accuracy than that for PET or CT alone. Caution in the interpretation of PET-positive SPN 
in regions where granulomatous pulmonary disease prevails is mentioned [17]. Owing to 
the hybrid imaging offered by 18F-FDG-PET-CT in combining the morphological 
appearances on CT and the metabolic behaviour of organs on PET, it has an advantage over 
the use of either modality alone [18]. Most studies which utilised 18F-FDG-PET-CT to 
evaluate variables that may be useful in predicting malignancy were directed at solitary 
pulmonary nodules [10, 11, 16]. We are unaware of any previous studies of the value of 18F-
FDG-PET-CT in diagnosing breast tuberculosis. In this study we evaluate the utility of 18F-
FDG-PET-CT in differentiating BTB from BCA.  
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PATIENTS AND METHODS 
Study design 
We conducted a non-randomized prospective observational study between January 2014 and 
January 2015. Ethical clearance was obtained from our institutions Biomedical Research 
Ethics Committee (Reference number BF213/13).  
Patients 
The study consisted of 29 patient’s 18F-FDG-PET-CT images from two cohorts, one with 
histologically proven BCA and the other with histologically proven BTB. 
Twenty four patients with histologically proven BCA who underwent pre-operative 18F-
FDG-PET-CT during the period January 2014 to September 2015 were retrospectively 
identified in our hospital’s database. The 18F-FDG-PET-CT images were retrieved from the 
picture archiving and communication system (PACS) and analysed retrospectively. 
Inclusion criteria were: histologically proven breast cancer, a radiologically proven breast 
lesion on the staging scan for either primary or recurrent breast cancer. In all cases of 
restaging, if the original baseline scan was done prior to treatment, this was sourced and used 
in the analysis. Pathology reports were reviewed and the following information was 
recorded; the histological type, and whether the breast cancer was newly diagnosed, 
recurrent or examination was for restaging following treatment was noted.  
Five consecutively identified patients with pathologically proven BTB were recruited and 
invited to have 18F-FDG-PET-CT after giving signed written consent to participate in the 
study. Four had conclusive histology, while one had inconclusive histology from breast and 
axilla, but had microbiologically proven pulmonary TB, for which she was receiving anti-
tuberculous therapy (ATT). Her clinical and radiological features were compatible with 
BTB. The biopsy was performed at the initial visit, and patients underwent 18F-FDG-PET-
CT scanning approximately three weeks after the initial visit, hence there was sufficient time 
to allow the biopsy sites to heal, thereby minimising interference with the PET-CT scan 
interpretation. 
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Methods 
18F-FDG-PET-CT image acquisition 
All patients fasted for at least six hours prior to an intravenous administration of 18F-FDG at 
a dose of 4 MBq/kg body weight. Glucose values were assessed before injection, with the 
maximum allowable glucose level prior to scan being 11.1 mmol/L. This was done in order 
to minimise the competition of high plasma glucose with 18F-FDG, which can result in the 
diversion of 18F-FDG into muscle, with a subsequent reduction in uptake by the 
inflammatory cells [19].  
A whole body PET-CT scan (Siemens, Erlangen, Germany) Biograph 16 slice was 
performed between 60 and 90 minutes after the injection. The PET images were acquired 
for a maximum of 8 bed positions at 3 minutes per field of view (FoV) in the craniocaudal 
direction, from the skull vertex to the mid-femur point. Images were acquired at a zoom of 
1 and a matrix of 168 x 168. An iterative reconstruction using 2 iterations and 24 subsets 
was used for post-acquisition image processing. 
A diagnostic non-contrasted CT scan was acquired in the craniocaudal direction with the 
following parameters: 4D CARE dose for 100 mAs, 120 KVp and 5 mm slice thickness, 
pitch of 0.75 for a scan time of 25s. A CT image multiplanar reconstruction was obtained 
using a kernel of B31f, abdomen window, slice thickness of 4 mm and a recon increment of 
2 mm. 
Combined 18F-FDG-PET-CT analysis 
The images were read by two experienced nuclear medicine physicians with ten years’ and 
five years’ experience respectively, and one of the authors, an experienced radiologist with 
15 years’ experience (DPR). Readings were agreed by consensus and there was no blinding.  
Quantitative analysis  
True-D software (Siemens, Erlangen, Germany) with automatic multi-planar orthogonal 
display of the 3-D regions of interest (ROI) in axial, sagittal and coronal planes, was used to 
analyse the fused and unfused 18F-FDG-PET-CT images. 3-D ROI were drawn over the 18F-
FDG avid areas, and the maximum standardised uptake value (SUVmax) of the FDG avid 
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breast lesions and axillary nodes were recorded. Bilateral axillary nodes were evaluated, and 
the highest SUVmax value was recorded. The corresponding CT images were evaluated for 
the density of the breast lesion and the axillary nodes in Hounsfield units (HU). If there were 
many adjacent nodes in a basin, these were considered as one, and the SUVmax and the HU 
of the whole basin was taken.  
Morphological analysis 
The lesions were grouped into four patterns: a mass, oedema, mass-oedema and thickening. 
The morphological characteristics were classified as solid, solid-cystic, axillary 
lymphadenopathy breast-oedema (ALBE) and thickening. 
Statistical analysis 
The two-sample t test with equal variances was used for differentiating the two groups. The 
results were considered significant where p values were <0.05. The relative frequencies of 
the various radiological patterns and morphologies were calculated using the Freeman-
Halton extension of the Fisher exact probability test for a two-rows by four-column 
contingency table and an online calculator (http://vassarstats.net/newcs.html). 
RESULTS 
Patient demographics and 18F-FDG-PET-CT qualitative findings 
All the patients were female, with age range for the BTB group being 23 to 42 years, and for 
the BCA cohort being 34 to 76. Amongst the BTB patients, three were HIV positive, one 
HIV negative and one not tested. BTB patients showed a mass (n=2), oedema (n=2) or 
thickening (n=1) pattern, while the majority of BCA patients had mass patterns (n=18). The 
mass-oedema pattern was only observed in the BCA group (n=4). There is a significant 
difference in the frequency of these patterns between the two groups (p=0.05). 
For morphological analysis, the solid morphology was only seen in the BCA group (n=17) 
(Fig. 1), whereas the ALBE morphology was only observed in the BTB group (n=2) (Fig. 
2). Both groups demonstrated solid-cystic morphology, with the BCA group having 6 (n=6) 
and the BTB group having 2 (n=2) (Fig. 3). Similarly, both groups had thickening 
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morphology, with one BCA (n=1) and one BTB patient (n=1) Fig. 4). These features are 
summarised in (Table 1). There is a highly significant difference in the frequency of these 
morphologies between the two groups (p=0.0007). 
The BCA pathological subtype were invasive ductal cancer (IDC) (n=22), invasive ductal 
adenocarcinoma (IDA) (n=1) and differentiated neuroendocrine (DNE) tumour (n=1). Of the 
29 women, 58.3% had 18F-FDG-PET-CT following prior treatment, whilst 41.7% had the 
scan prior to any treatment. The findings are summarised in (Fig. 5).  
Quantitative 18F-FDG-PET-CT findings 
The mean (SD) SUVmax of the breast lesions in the BCA patients were significantly higher 
than those of the BTB patients at baseline, 12.59±8.11 vs 3.14±1.55 respectively, (p=0.016). 
There was no statistically significant difference in the baseline mean SUVmax of the axillary 
lymph nodes, the breast lesions density (HU) and the axillary lymph nodes density (HU). 
These are summarised in Table 2. 
DISCUSSION 
BTB is an uncommon manifestation of extra-pulmonary tuberculosis (EPTB); and may have 
a more severe presentation when associated with HIV infection [20, 21]. BTB can be 
effectively treated medically in most cases [4], making early diagnosis important. The 
features of BTB are similar to and may overlap those of BCA [22]. Furthermore BCA and 
BTB can co-exist, and patients with TB-HIV co-infection who develop BCA are at risk of 
being misdiagnosed [23-25]. The importance of discriminating these two conditions can 
therefore be challenging, particularly in the setting of TB-HIV co-infection.  
Our results show that the mean SUVmax for the breast lesion is higher in patients with BCA 
than in those with BTB. SUVmax appears to be a strong discriminator between breast cancer 
and breast tuberculosis when the lesion is located within the breast or chest wall, (p=0.016). 
This result is in keeping with some recent studies utilising 18F-FDG-PET-CT in assessing 
solitary pulmonary nodules (SPN). Lopez et al retrospectively analysed 18F-FDG-PET-CT 
scans of fifty-five patients with SPN using a combination of quantitative parameters; 
maximum diameter on CT (Dmax) and SUVmax; and demographic variables. Their study 
found the predictive model incorporating SUVmax values and patient age was the best 
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discriminator between benign and malignant SPN [10]. In another study, Yilmaz et al 
retrospectively reviewed 18F-FDG-PET-CT of 241 patients with SPN, and found the mean 
SUVmax value was statistically significantly higher in patients with the SPN diameter ≥ 1cm 
hence was useful for differentiating benign from malignant nodules above this size [11].  
On the other hand, in our study the SUVmax was not useful in differentiating between 
tuberculous and metastatic axillary lymphadenopathy (p=0.411). This is in agreement with 
a study that attempted to differentiate benign from malignant solitary pulmonary nodules in 
a population in which TB is endemic, where 18F-FDG-PET-CT failed to distinguish the two 
conditions [16]. It therefore appears that the SUVmax is a good discriminator of BTB and 
BCA for the intra-mammary breast lesions and not for axillary lymph nodes. Lesion density 
HU was not useful in differentiating between the breast lesions (p=0.566) and the axillary 
nodes (p=0.101) of the BTB and BCA patients.  
The three morphological patterns of mass, oedema and thickening were observed in both the 
BTB and the BCA patients. However, mass-oedema was only observed in the BCA patients. 
Although our numbers are small, this may suggest that breast masses associated with oedema 
on 18F-FDG-PET-CT are more likely to be cancer than TB. Similarly, although the solid-
cystic and the thickening morphologies were present in both groups, the solid morphology 
was only observed in the BCA group, and the ALBE pattern only in the BTB group. It 
therefore appears that when the breast oedema without a mass is associated with axillary 
lymphadenopathy, it is more likely to be TB than cancer.  
Owing to the low prevalence of BTB, the small sample size cannot at this stage do more than 
flag possible areas of divergence of the two diseases. The changes we have shown however 
suggest that a pooled multinational study with larger numbers may be useful in developing 
diagnostic algorithms for the radiological diagnosis of BTB. 
STUDY LIMITATIONS 
Given the small sample size, our conclusions are preliminary. 
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FIGURE LEGENDS 
Figure 1 
Axial 18F-FDG-PET-CT image of an 86 year old woman with left breast cancer, 
demonstrating a rounded strongly 18F-FDG avid mass and perilesional increased metabolic 
activity in the left breast consistent with the solid morphological characteristic. The left 
breast is significantly larger than the right. Moderate metabolic activity present adjacent to 
the calcified fibrotic right lung changes from old PTB. 
Figure 2 
Axial 18F-FDG-PET-CT image of a 36 year old woman with left breast tuberculosis, showing 
left breast enlargement and hypermetabolic 18F-FDG avid enlarged left axillary nodes 
consistent with axillary lymphadenopathy and breast oedema (ALBE).  
Figure 3 
Axial 18F-FDG-PET-CT image of a) A 45 year old woman with left breast cancer and b) A 
23 year old woman with right breast tuberculosis, extending into the underlying chest wall. 
The white arrows in both images demonstrate photopaenic areas which represent the 
cystic/necrotic centres, whilst the blue arrows show the 18F-FDG avid solid components of 
the solid-cystic morphology.  
Figure 4 
Axial 18F-FDG-PET-CT images of a) A 76 year old woman with right breast cancer and b) 
A 38 year old woman with right breast tuberculosis. The blue arrows on both images 
demonstrate the thickening in the axillary tail. The white arrow on image b) represents the 
metabolically active right axillary nodes.  
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Figure 5 
Morphological characteristics of breast tuberculosis (n=5) and breast cancer (n=24) patients 
on 18F-FDG-PET-CT. IDC=invasive ductal cancer; IDA=invasive ductal adenocarcinoma; 
DNE=differentiated neuroendocrine tumour. 
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TABLE 1 
18F-FDG-PET-CT Qualitative features for breast cancer and breast tuberculosis patients. 
ALBE” Axillary lymphadenopathy and breast oedema. 
Qualitative feature BTB patients (n=5) BCA patients (n=24) 
Patterns 
Mass 2 18 
Oedema 2 1 
Mass-oedema 0 4 
Thickening 1 1 
Morphology character 
Solid 0 17 
Solid-cystic 2 6 
ALBE 2 0 
Thickening 1 1 
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TABLE 2 
18F-FDG-PET-CT Quantitative parameters for breast cancer and breast tuberculosis patients. 
SD: standard deviation. 
Parameter BTB (baseline) BCA P value 
Mean±SD SUVmax breast 
lesion 
3.14±1.55 
(95% CI, 1.21-5.06) 
12.59±8.11 
(95% CI, 9.16-16.01) 
0.016* 
Mean±SD SUVmax 
axillary nodes 
6.99±3.51 
(95% CI, 2.62-11.36) 
9.91±7.55 
(95% CI, 6.64-13.17) 
0.411 
Mean±SD HU breast 
lesion 
331.60±269.11 
(95% CI, -2.54-665.74) 
405.16±255.61 
(95% CI, 297.23-513.10) 
0.566 
Mean±SD HU axillary 
nodes 
192.4±285.94 
(95% CI, -162.65-547.45) 
393.60±230.53 
(95% CI, 293.91-493.29) 
0.101 
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ABSTRACT 
Aim 
The aim of this study was to evaluate the value of diffusion weighted imaging (DWI), T2W 
and dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) in differentiating 
breast cancer (BCA) from breast tuberculosis (BTB). 
Methods 
We retrospectively studied images of 18 patients with BCA who had undergone pre-
operative MRI and 6 patients with pathologically proven BTB who underwent dynamic 
contrast enhanced (DCE-MRI) during the period January 2014 to January 2015. 
Results 
All patients were female, with the age range of BTB patients being 23-43 years, and the 
BCA patients being 31-74 years. BCA patients had a statistically significant lower mean 
apparent diffusion coefficient (ADC) value (1072.10±365.14) compared to the BTB group 
(1690.77±624.05, p=0.006). The mean T2 weighted signal intensity (T2SI) was lower for 
the BCA group (521.56±233.73) than the BTB group (787.74±196.04, p=0.020). An ADC 
mean cut-off value of 1558.79 yielded 66% sensitivity and 94% specificity whilst the T2SI 
cut-off value of 790.20 yielded 83% sensitivity and 83% specificity for differentiating 
between BTB and BCA. Our results suggest that these parameters were better able to 
distinguish the two groups when a morphological enhancement pattern was one of a mass 
lesion, rather than non-mass enhancement (NME). 
Conclusions 
Multi-parametric MRI incorporating the DWI, T2W and the DCE-MRI may be a useful tool 
to differentiate BCA from BTB. 
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INTRODUCTION 
While breast cancer (BCA) is the most prevalent malignancy amongst South African women, 
accounting for 20.62% [1], the prevalence of breast tuberculosis (BTB)  is by contrast very 
much lower, with reported ranges between 0.3% - 0.4% [2, 3]. BTB is a manifestation of 
extra-pulmonary tuberculosis (EPTB), a condition which has become considerably more 
commonly encountered as a consequence of the human immunodeficiency virus (HIV) 
pandemic [4, 5], yet  studies and guidelines on the management of EPTB frequently do not 
mention the breast as a potential site for tuberculosis [6-8]. Given the infrequency with which 
BTB is diagnosed, little research has been performed on the disease. BTB and BCA may 
present clinically in a very similar fashion leading to potential misdiagnosis [9, 10]; given 
that an accurate diagnosis is essential if the patient is to receive correct and timely treatment, 
this may be problematic [8] 
Conventional imaging with mammography and ultrasound has limited ability to differentiate 
between BTB and BCA [11]. It is therefore appropriate to investigate the use of newer and 
more complex imaging modalities in the differentiation of BCA and BTB. Studies that have 
used MRI to differentiate EPTB from malignant lesions are those which focused on other 
body parts such as the central nervous system (CNS) [12-14] and the musculoskeletal system 
[15, 16]. Peng et al used the diffusion weighted imaging (DWI) and magnetic resonance 
spectroscopy (MRS) to differentiate intracranial tuberculomas from high grade gliomas and 
found significant differences. The diagnostic accuracy was higher when using the minimum 
ADC value from the DWI than the maximum MRS ratios of Cho/Cr, Cho/NAA, and 
Cho/Cho [13]. MRI has also been utilised in pulmonary tuberculosis (PTB) to differentiate 
between tuberculoma nodules and the malignant ones [17-20]. Only one study was found in 
the literature which aimed to differentiate BTB from BCA with the use of magnetic 
resonance spectroscopy (MRS) in four BTB patients with no comparison group [21].  The 
authors suggested that the absence of choline peak and the presence of a strong lipid peak 
favoured BTB rather than BCA [21].  
The studies that focused on using MRI in discriminating malignant breast lesions from 
benign breast disease do exist [22-27]. Rong-Feng Qu et al recently conducted a meta-
analysis of the differential diagnosis of benign and malignant breast tumours. The authors 
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found that the ADC values of normal breast tissues were higher than those of benign tissues, 
and that the values of benign lesions were higher than of malignant tumours [23].  
DWI measures the microscopic movement of water molecules in biological tissues, with the 
pathologic processes altering their mobility, the detection of these changes aid in lesion 
characterisation [28]. The apparent diffusion coefficient (ADC) maps from the DWI are 
automatically displayed on the MRI workstations. Tissues with high ADC values, due to 
increased diffusion, display a brighter signal, whereas those with lower ADC values appear 
darker, due to restricted diffusion [29]. Most malignant lesions display lower ADC values 
when compared to benign or inflammatory lesions [26]. 
Breast DCE-MRI involves administration of magnetic compatible intravenous (I.V) contrast 
agent in order to detect and characterise lesions [30]. Further advantage is the ability to 
evaluate the breast lesion enhancement parameters and kinetic curves [31]. It has been shown 
that the kinetic parameters have correlation with the immuno-histochemical surrogates of 
tumour neovascularity [32].  
The T2 weighted (T2W) MRI uses the tissue transverse relaxation times to generate the 
signal [33]. The displayed T2 signal intensity (T2SI) is used in the characterisation of tissues 
and lesions [33]. Studies that used the T2SI in the discrimination of benign and malignant 
breast lesions mainly analysed the morphologic T2SI appearance rather than the quantitative 
values [34, 35]. Majority of breast cancers appear hypointense on T2W compared to most 
benign lesions which appear hyperintense [36].  
The purpose of our study was to evaluate the use of the DWI parameter of ADC, the DCE-
MRI enhancement morphologic characteristics and the T2W parameter of T2 signal intensity 
value to differentiate BCA from BTB.  
PATIENTS AND METHODS 
We retrospectively identified 25 patients with histologically proven BCA (including ductal 
carcinoma in situ (DCIS) and lobular carcinoma in situ (LCIS) who underwent DWI, T2W 
and DCE-MRI during the period January 2014 to December 2014. Seven patients did not 
have a full set of images on the picture archiving and communication system (PACS) and 
were excluded from the study, which resulted in the final total of 18 patients. 
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For the BTB group, we included six prospectively and consecutively identified patients with 
proven BTB who also underwent the DWI, T2W and DCE-MRI. While five had conclusive 
histology from either the breast or the axillary lymph nodes, one had inconclusive histology 
from breast and axilla, but had proven concurrent PTB, for which she was receiving anti-
tuberculous therapy (ATT). Her clinical and radiological features were compatible with 
BTB, and both the breast and the axillary nodes responded satisfactorily to ATT. All BTB 
patients had undergone screening investigations at the referring breast clinic, including 
ultrasonography, with or without mammograms, depending on their age. Following the 
histological confirmation of BTB, the patients were invited for a baseline MRI scan within 
two weeks of confirmation of diagnosis. Scans were not performed within two weeks of a 
biopsy in order to avoid the presence of haematoma and/or inflammation confounding our 
results. 
MRI image acquisition 
MRI images were retrospectively analysed following retrieval from the hospital’s picture 
archiving and communication system (PACS). MRI was performed on a 1.5T machine 
(Siemens, Erlangen, Germany) using a dedicated breast coil. The patients were scanned in 
the prone position. A power injection of 20 ml intravenous (I.V) Magnevist® (Gadopentetate 
Dimeglumine, Bayer) Standard 469 mg/mL (0.5 mmol/mL) at a dosage of 0.1 mmol/kg was 
administered to all the patients. The IV contrast rate was 3ml/sec followed by a 20 ml saline 
flush administered as a bolus. The T1 dynamic phase scan time was 6 minutes 41 seconds, 
during which 5 dynamic sequences were obtained in the axial position at various time points. 
The DWI images with the ADC map were also acquired during the same scan. The technical 
parameters are reported in Table 1.  
MRI image analysis 
All the images were read by one of the authors (DPR), a radiologist with more than ten years’ 
experience of breast radiology. The following qualitative parameters were recorded: The 
breast cancer pathological subtype from the pathology records; The DCE-MRI parameters 
included: the enhancement pattern, the lesion morphology and the distribution pattern. The 
enhancement pattern was classified as either mass like enhancement (MASS) or non-mass  
enhancement (NME) [37]; the lesion morphology was classified as solid, solid-cystic, focal, 
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necrotic or axillary nodes; and the distribution pattern as unifocal, multifocal, multicentric, 
segmental or diffuse [37]. We further recorded the apparent diffusion coefficient (ADC) 
values (x10-6mm2/sec) derived from the DWI images; and T2SI value derived the T2W. For 
the quantitative parameters, the region of interest (ROI) was drawn on the axial images 
around the lesion circumference. All images were analysed on the dedicated Syngo-via 
(Siemens, Erlangen, Germany) reading platform.   
Statistical analysis 
Data were entered into an Excel spreadsheet (Microsoft Excel 2013. Redmond, WA) and 
analysed using the STATA software package (StataCorp. 2015: Stata Statistical Software, 
Release 14. College Station, TX). Differences in ADC value and T2SI between the two 
groups were assessed with a two-tailed unpaired t test. Differences in ADC value and T2SI 
with enhancement pattern matching were assessed using analysis of variance (ANOVA). 
The results were considered significant where p <0.05.  
Ethical clearance 
Ethical clearance was obtained from the institution Biomedical Research Ethics Committee 
(BREC) (Reference number BF213/13).  
RESULTS 
Patient characteristics 
All the patients were female. The ages of the BTB patients ranging from 23-43 years, for 
those with BCA 31-74 years. Three BTB patients, were HIV positive, one HIV negative and 
one not tested. The BCA subtypes included; 12 cases of invasive ductal cancer (IDC) 
(67.5%), three cases of DCIS (16.5%), of whom one had high grade DCIS, and one case 
each (5.5%) of invasive lobular cancer (ILC), invasive ductal adenocarcinoma (IDA), and 
lobular carcinoma in situ (LCIS). 
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Radiologic findings 
The MRI morphological characteristics of the patients are summarised in (Fig. 1). We found 
significant differences in both ADC and mean T2SI values between the two groups. BCA 
patients had a significantly lower mean ADC value (1072.1±365.1) compared to those with 
BTB (1690.8±624.1), (p=0.006). The BCA group had a lower mean T2SI (521.6±233.7) 
compared with the BTB group (787.7±196.0) (p=0.020). These findings are summarised in 
(Table 2). In terms of predictive ability, we performed a preliminary ROC curve analysis 
and showed a 67% sensitivity and 94% specificity for an ADC cut-off value of 1558, with 
an AUC of 0.81 (95% CI 0.57-1.05) (Fig. 2). The corresponding values for a T2SI cut-off 
value of 790 were sensitivity 83% and specificity 83%, with an AUC of 0.77 (95% CI 0.54-
0.96) (Fig. 3).  Our total number of observations is however small, and a larger test sample 
will be necessary to play such a test on a firm footing. The representative images 
demonstrating data extraction for ADC values and T2SI measurements of the BCA and BTB 
patients are depicted in (Fig. 4).  
Breast cancer versus breast tuberculosis with matched patterns 
These differences persisted when the two groups were matched for the patterns of mass-like 
enhancement (MASS) and non-mass enhancement (NME) and compared with ANOVA. 
Significance was shown for both mean ADC value (p=0.040) and T2SI (p=0.015). Tukey 
post-hoc test comparisons identified a number of pairings for which the difference is 
significant as follows; 
For ADC: BTB (mass-like enhancement) versus BCA (mass-like enhancement) (p=0.037) 
and BTB (non-mass enhancement) versus BCA (mass-like enhancement), (p=0.016); and 
for T2SI: BTB (mass-like enhancement) versus BCA (mass-like enhancement) (p=0.021); 
BTB (non-mass enhancement) versus BCA (mass-like enhancement) (p=0.011); and BCA 
(mass-like enhancement) versus BCA (non-mass enhancement) (p=0.027).  
DISCUSSION 
This study evaluated the ability of the two quantitative MRI markers, the ADC value and the 
T2SI and the qualitative dynamic post contrast enhancement patterns to discriminate 
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between BCA and BTB. We have shown that BCA patients have significantly lower mean 
ADC and T2SI values compared to the BTB. This outcome is explicable in that malignant 
lesions have high cellularity with resulting restricted diffusion, yielding lower ADC values, 
a parameter derived from the DWI. This finding has been shown to be consistent across 
many studies [23-27, 38, 39], with few exceptions [12]. Woodhams et al. [24] found 
malignant breast tumours to have higher ADC values than the benign lesions furthermore 
the invasive ductal cancers (IDC) displayed lower values when compared to the non-invasive 
ductal cancer (NIDC).  In contrast, Chatterjee et al. [12] found similar ADC values for brain 
tuberculomas and brain metastases. In our study the ADC value appeared to be the better 
discriminator between BCA and BTB. A preliminary ROC curve suggested an optimal ADC 
cut-off value at 1558.8 and a T2SI cut-off at 790.20 with a sensitivity and specificity of 66% 
and 94% respectively. The confidence intervals are however wide and further validation is 
required before these can be accepted as accurate figures for discrimination. 
The studies that utilised the T2SI to discriminate the benign from the malignant breast lesions 
predominantly focused on the qualitative T2 signal morphologic appearance rather than the 
quantitative value as in our study [34, 35]. The data on the use of quantitative T2SI as a 
discriminator between benign and malignant breast lesions is scanty [40]. Other studies in 
which T2SI quantitative values were used in differentiating benign from malignant lesions 
involve other parts of the body and not the breast [41, 42]. Henz Concatto et al. [41] 
investigated pulmonary nodules with MRI using quantitative parameters ADC and T2SI in 
a granulomatous endemic area. They found both the mean T2SI ratio and the ADC to be 
significant in differentiating the benign from the malignant pulmonary nodules. 
Given the limitations of post-hoc analysis, our study may suggest that discriminatory 
performance is not homogeneous across all morphological enhancement patterns exhibited 
by lesions; the discriminatory value of tests based on ADC and T2SI may be higher for some 
morphological appearances than for others. Our findings suggest that these tests are more 
discriminatory for a mass-pattern post-contrast appearance rather than when the pattern is of 
non-mass enhancement (NME). The Breast imaging-reporting and data system (BI-
RADS)[37] morphologic descriptor and internal enhancement patterns of non-mass 
enhancement have been found to be unreliable in predicting the likelihood of malignancy by 
other studies [43, 44]. In a study of 258 MRI examinations of suspicious BI-RADS category 
4 and 5 lesions, the differences in lesion size, margins and enhancement patterns were useful 
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in predicting malignancy for masses, but were not useful for non-mass enhancement [43]. 
We have shown that the T2SI was better able to detect a significant difference (p=0.027), 
than the ADC (p=0.276) when the BCA mass pattern was compared with the BCA NME 
pattern. Although there is data from many studies [22, 25, 27] that used the ADC value to 
differentiate benign from malignant breast lesions, they did not incorporate the enhancement 
pattern matching into the methodology. There is paucity of studies [38, 45] which evaluated 
the value of ADC in discriminating benign from malignant breast lesions with inclusion of 
the enhancement pattern. Partridge et al suggested that the ADC values may be more 
beneficial for mass lesions than for the NME [45], which is similar to our finding. Similarly, 
Imamura et al found the use of ADC values did not adequately improve DCE-MRI 
performance for the differential diagnosis of non-mass-like breast lesions however, the 
addition of the ADC value criteria to the DCE-MRI pattern analysis improved sensitivity, 
NPV and accuracy [38]. 
The BI-RADS lexicon defines the NME pattern as an area of enhancement that is distinct 
from the surrounding parenchyma. It does not represent a space-occupying mass (<5mm), 
and is typically interspersed with non-enhancing fatty or glandular breast tissue [37]. This 
leads us to believe that the ADC value of the tumour cells and the intervening normal breast 
tissues cannot be reliably measured when the tumour cells are scattered randomly in a NME 
pattern, rather than grouped discreetly into a mass. The differential diagnosis of the NME 
pattern includes both benign [46, 47] and malignant causes [39, 48, 49]. Therefore it is clear 
that the NME pattern on its own cannot be used to differentiate between benign and 
malignant conditions. However, when other imaging markers are taken into account, the use 
of NME patterns can be useful. The T2SI measures the transverse relaxation times of tissues 
in order to provide image contrast [33]: it is unclear why the T2SI does not appear to be 
influenced by the enhancing pattern.  
The enhancement morphological pattern of completely solid mass and the distribution 
pattern of segmental, multifocal and multicentric were exclusive for BCA. On the other hand 
both the BCA and the BTB lesions displayed the unifocal and the diffuse distribution 
patterns. These qualitative features can be used as descriptors for separating the two 
conditions when the other imaging or pathology results are equivocal.  
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Based on our findings, we conclude that the combination of dynamic contrast enhanced MRI 
morphologic enhancement pattern, the quantitative T2SI and the quantitative DWI ADC 
values may provide some useful non-invasive information in distinguishing malignant from 
non-malignant illness (in this case, BTB) in patients with suspicious breast lesions. 
Development of accurate diagnostic algorithms will require the accumulation of a larger 
patient database for BTB in particular; more broadly however, continued investigation is 
appropriate in terms of the development of tests to distinguish malignant from benign disease 
more generally.  
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FIGURE LEGENDS: 
Figure 1 
Morphological characteristics of the breast cancer and breast tuberculosis patients on DCE-
MRI demonstrating; a) The enhancement pattern. b) The morphological pattern. c) The 
distribution pattern.  
Figure 2 
Preliminary ROC curve analysis of the ADC value of the breast lesions for differentiating 
cancer from tuberculosis.  
Figure 3 
Preliminary ROC curve analysis of the T2 signal intensity of the breast lesions for 
differentiating cancer from tuberculosis.  
Figure 4 
ADC value and the T2SI measurements.  
(A-C): Axial DCE-MRI, DWI and T2W-MRI images of a 61 year old woman patient with 
left breast cancer. a)  Axial T1post-contrast subtracted image demonstrate strongly 
enhancing mass with neovascularity in the left breast; b) Corresponding axial DWI-MRI 
ADC map image shows dark signal; and c) Axial T2 weighted image shows the tumour 
hypointensity.  
(D-F): Axial DCE-MRI, DWI and T2W-MRI images of a 41 year old woman patient with 
left breast tuberculosis. d)  Axial T1post-contrast subtracted image demonstrate a 
hypointense rim-enhancing mass in left breast; e) Corresponding axial DWI-MRI ADC map 
image demonstrate a bright signal; and f) Axial T2 weighted image shows a uniformly 
hyperintense signal. 
 
135
18
TABLE 1 
Local dynamic contrast-enhanced breast MRI protocol technical parameters. TSE=Turbo Spin Echo; GE=Gradient Echo; STIR=Short Tau 
Inversion Recovery. 
MRI sequence Acquisition 
plane 
Repetition 
time (TR) 
(msec) 
Echo Time 
(TE) (msec) 
Inversion 
time (msec) 
Matrix size Field of 
view (FoV) 
(mm) 
Slice 
thickness 
(mm) 
Voxel size 
(mm) 
Localizer sagittal 7.6 3.53 - 384 x 512 400 6 2.1x1.6x6.0 
T1 precontrast GE 3D  axial 8.6 4.70 - 299 x 384 320 1 1.0x0.7x1.0 
T1 GE 3D dynamic sequences 
( 1 pre& 5post contrast)  
axial 9.1 4.76 - 299 x 284 340 1.5 1.1x0.9x1.5 
T1 3D Dixon axial 7.20 first 2.38; 
second 4.76 
- 320 x 320 340 1.8 1.1x1.1x1.8 
T1 fat sat axial 680 10 - 224 x 320 320 4 1.4x1.0x4.0 
T2 STIR axial 5600 59.0 170 314 x 320 340 4 1.1x1.1x4.0 
T2 TSE axial 6100 111 - 384 x 512 320 4 1.7x1.3x4.0 
DWI b values 0 & 800s/mm2 axial 9200 86 180 150 x 192 380 4 2.0x2.0x4.0 
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TABLE 2 
Comparison of the DWI and T2W-MRI imaging quantitative parameters for the breast 
tuberculosis and breast cancer patients. 
Parameter BTB 
(Mean ± SD) 
(n = 6) 
BCA 
(Mean ± SD) 
(n = 18) 
P value 
ADC (x10-6mm2/sec) 1690.8±624.1 
(95% CI 1035.9 – 2345.7) 
1072.1±365.1 
(95% CI 890.5 – 1253.7) 
0.006 
T2 signal intensity 
value (T2SI) 
787.7±196.0 
(95% CI  582.0 – 993.5) 
521.6±233.7) 
(95% CI 405.33 – 637.8) 
0.020 
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CHAPTER 7 
Comparative study of breast lesion size evaluation using DCE-MRI at 1.5T 
and 18F-FDG- PET-CT in seven patients with breast tuberculosis or breast 
cancer 
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ABSTRACT 
Aim 
The aim of the study was to compare the values of breast lesion volume and maximum diameter 
as measured by dynamic contrast-enhanced breast MRI (DCE-MRI) and prone 18F-FDG-PET-
CT imaging.  
Methods 
7 patients who underwent both 18F-FDG-PET-CT and DCE-MRI with an interval not 
exceeding one month were studied. For both modalities, True-D software was used and the 3-
D volume of interest (VOI) was drawn around the 18F-FDG avid areas on PET-CT. We 
recorded the breast lesion volume and maximum diameter (Dmax). 
Results 
A total of 9 lesions from the 7 patients were found. The mean Dmax was 8.1 ± 3.6 cm and 9.7 
± 5.1 cm when using DCE-MRI and 18F-FDG-PET-CT respectively. The mean lesion volume 
was 281.0 ± 406.8 cm3 for DCE-MRI and 319.4 ± 421.8 cm3 for 18F-FDG-PET-CT. For both 
lesion volume and Dmax, there was a strong correlation between modalities with coefficients of 
determination (R2) of 0.986 and 0.931 respectively (p <0.0001). However 18F-FDG-PET-CT 
returned significantly higher values for both the Dmax and the lesion volume, (p=0.032) and 
(p=0.05) respectively.  
Conclusion 
Breast lesion volume and maximum diameter measured by 18F-FDG-PET-CT and DCE-MRI 
show a strong correlation between the two modalities. Both can be used in the treatment 
monitoring of breast lesions. There is however a difference in the absolute measurements, and 
they should not be used interchangeably. 
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INTRODUCTION 
The management of breast cancer is being constantly updated in line with advances in imaging 
technologies which improve the correct staging [1]. The basic radiological tests for breast 
cancer staging are mammography and ultrasound [2, 3], however the move towards individual 
targeted therapy has contributed to the increasing use of both 18F-FDG-PET-CT and breast 
DCE-MRI in management algorithms [4, 5]. In view of the continually evolving diagnostic and 
staging methods, the international guidelines for breast cancer management are regularly 
revised [2]. Since 2008, the newer imaging modality of hybrid PET-MRI has been studied for 
use in breast cancer management [6]; using either sequential image acquisition as in PET-CT, 
or simultaneous image acquisition in an integrated device [7]. 
Indications for the use of DCE-MRI in breast cancer management include both screening and 
management of manifest disease [3, 8]. MRI screening has been recommended for women with 
a life time breast cancer risk of more than 20%; and for those who have had previous breast 
augmentation in whom mammographic screening is difficult [2, 8]. MRI indications in 
symptomatic disease include: the preoperative staging of newly diagnosed breast cancer; 
further evaluation of equivocal clinical and radiological findings; for baseline and monitoring 
of neoadjuvant chemotherapy (NAC); for the investigation of unknown primary; and for the 
evaluation of local tumour recurrence when conventional imaging is equivocal [1, 2, 8, 9]. 
Although there are other PET tracers in use or under study [7, 10], 18F-FDG is the most 
commonly used and has an established role in oncology [11]. 18F-FDG-PET indications in 
breast oncology include: baseline staging in locally advanced breast cancer in which the tumour 
is large but operable (stages 11B and 111A) or there is skin, chest wall and/or high burden 
nodal disease (stages 111B and 111C) [5]; the suspicion of metastatic disease when 
conventional imaging is equivocal [5, 11] and the follow-up of metastases or recurrence when 
conventional imaging is equivocal; [11]. 18F-FDG-PET has additionally been recommended 
for monitoring response to NAC although it has been mentioned as optional by the National 
Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN 
Guidelines®) version 3, 2014 [12]. 
18F-FDG-PET-CT hybrid imaging in breast cancer has the advantage of providing information 
on the morphological CT features and the metabolic nature of the primary tumour, as well as 
evaluating for distant disease [13]. In contrast to dedicated breast MRI, it has the further 
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advantage of imaging the whole body and not just the immediate breast region except in 
facilities where whole body MRI is available and routinely applied in the staging pathway [10]. 
Breast DCE-MRI has the advantage of providing good soft tissue contrast and definition of 
morphological features of the primary tumour [2, 14]. Furthermore MRI does not use ionising 
radiation hence it is a safer option in paediatric and pregnant patients than PET-CT [15]. 
Studies comparing the diagnostic performance of PET-CT and breast DCE-MRI suggest that 
MRI is more sensitive in the evaluation of tumour size and breast lesion detection [16-21]. 
However, equivalent diagnostic performance between MRI and PET-CT for the evaluation of 
the axillary lymph nodes was found in some studies [20, 22]. 
The correct measurement and documentation of the local tumour size with various imaging 
modalities in patients with breast cancer is critical because it influences treatment choices and 
decisions [9]. In this study, our aim was to evaluate whether there is correlation between the 
parameters, namely: the breast lesion volume and the maximum diameter measured on 18F-
FDG-PET-CT and dedicated breast DCE-MRI.  
PATIENTS AND METHODS 
Nine lesions from seven patients who underwent 18F-FDG-PET-CT between January 2014 
and July 2015 were analysed. All patients had undergone both prone 18F-FDG-PET-CT 
and prone breast DCE-MRI within two weeks of each other. Ethical clearance was obtained 
from our institution’s Biomedical Research Ethics Committee (Ref BF213/13). 
The five breast tuberculosis patients had undergone screening investigations at the referring 
breast clinic, including ultrasonography with or without mammograms depending on the 
patient’s age. Following the histological confirmation of BTB, the patients were invited for a 
baseline 18F-FDG-PET-CT and DCE-MRI scans. The other two patients’ records were 
retrieved from the database between January 2014 and December 2014 and this was done by 
identifying those patients who had had both modalities performed within two weeks of each 
other. A total of nine lesions in seven patients were studied.  
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18F-FDG PET-CT image acquisition 
All patients fasted for at least 6 hours prior to the intravenous administration of 18F-FDG in a 
dose of 4 MBq/kg body weight (range 192-261MBq, 5.17-7.05mCi). Glucose values were 
obtained before injection. All the patients had an acceptable glucose level not exceeding 
11.1mmol/L in order to minimise the competition of high plasma glucose with 18F-FDG, which 
can result in the diversion of 18F-FDG into muscle [23].  
 A whole body PET-CT scan with 16 slice Biograph (Siemens, Erlangen, Germany) was 
performed between 60 and 90 minutes after the injection. The PET images were acquired for a 
maximum of 8 prone bed positions at 3 minutes per field of view (FoV) in the cranio-caudal 
direction commencing at the skull vertex and terminating at the mid-femur point. The images 
were acquired at a zoom of 1 and a matrix of 168 x 168. An iterative reconstruction using 2 
iterations and 24 subsets was used for the post-acquisition image processing. 
A diagnostic non-contrasted CT scan was acquired in the cranio-caudal direction using the 
following parameters: 4D CARE dose for 100mAs, 120 KVp and 5 mm slice thickness, pitch 
of 0.75 for a scan time of 25s. A CT Image multiplanar reconstruction was obtained using a 
kernel of B31f, abdomen window, slice thickness of 4 mm and a recon increment of 2 mm. 
Quantitative 18F-FDG-PET-CT and DCE-MRI image analysis  
All the images were read by one experienced nuclear medicine physician with ten years of 
experience and one of the authors, an experienced radiologist with 20 years of experience 
(DPR). Agreement was reached by consensus.  
True-D software with automatic multi-planar orthogonal display of the volume of interest 
(VOI) in axial, sagittal and coronal planes, was used to analyse the fused 18F-FDG-PET-
CT images and the DCE-MRI images. 3-D VOI were drawn around circumference of 18F-
FDG avid areas on PET. A visual correlation of the same anatomical lesion on subtracted 
dynamic post contrast T1 breast DCE-MRI images was performed. The 3-D VOI was 
drawn around the circumference of the enhancing lesion (Fig. 1). For MRI, the lesion 
anatomical borders were used to determine diameter and volume. For FDG-PET-CT,  
the volume of interest (VOI’s) were mapped visually to cover borders of the lesion, 
and isocontours of 20% SUVmax were generated.  
149
6
The following parameters were recorded; a) lesion volume, b) lesion maximum diameter 
(Dmax).  
MRI image acquisition 
MRI was performed on a 1.5T machine (Siemens, Erlangen, Germany) using the dedicated 
breast coil. Scans were done in the prone position. MRI was performed on a 1.5T machine 
(Siemens, Erlangen, Germany) using a dedicated breast coil. The patients were scanned in 
the prone position. Power injection of 20 ml intravenous (I.V) Magnevist® (Gadopentetate 
Dimeglumine, Bayer) Standard 469 mg/mL (0.5 mmol/mL) at a dosage of 0.1 mmol/kg was 
administered to all the patients. The IV contrast rate was 3 ml/sec followed by a 20 ml saline 
flush administered as a bolus. The T1 dynamic phase scan time was 6 minutes 41 seconds, 
during which 5 dynamic sequences were obtained in the axial position at various time points. 
The technical parameters are shown in Table 1.  
Statistical analysis 
Data were entered into a Microsoft Excel spreadsheet (Microsoft Excel 2013, Microsoft 
Corporation, Redmond, WA) and analysed using MedCalc for Windows, version 15.11.4 
(MedCalc Software, Ostend, Belgium). The correlation of lesion volume (VL) and lesion 
maximum diameter (Dmax) on the two modalities of 18F-FDG-PET-CT and DCE-MRI was 
assessed using linear regression. The paired t test was used to compare differences in means 
between the two tests. A p value <0.05 was considered significant.  
RESULTS 
All the patients were female with an age range of 23 to 48 years. There were two malignant 
lesions and seven TB lesions. Patient ID number 2 on table 2 had three lesions. Amongst the 
five BTB patients, three were HIV positive, one negative and one unknown. 
The results are summarised in Table 2. The measured maximum diameter of the lesions was 
significantly larger on 18F-FDG-PET-CT than on DCE-MRI (p=0.03). Similarly, the 
measured lesion volume was significantly larger on 18F-FDG-PET-CT than on DCE-MRI 
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(p=0.05). In both cases the measured dimensions correlated highly between the two 
modalities (R2 for Dmax=0.931, R2 for volume=0.986, p<0.0001). 
DISCUSSION 
The use of 18F-FDG-PET-CT and DCE-MRI in the staging of breast cancer influences 
treatment decisions [1]. The breast lesion measurements obtained from either modality play 
a role in the initial staging and in the follow-up scans [2]. We aimed to determine the 
correlation in measured size of the breast lesion between the two modalities.  
We found that the measured volume (LV) and the maximum diameter (Dmax) for the breast 
lesions using 18F-FDG-PET-CT and DCE-MRI are highly correlated, though the absolute 
value differs significantly. This suggests that either of the two modalities may be used in the 
response evaluation, provided a single modality is used consistently. Our findings are 
supported by data from studies which confirm that there is good correlation between breast 
DCE-MRI and PET-CT in the evaluation of the primary breast tumour size [24-26]. Pace et 
al, (2014) found a good correlation between PET-CT and PET-MRI hybrid systems for the 
lesion detection, SUV values and the metabolic tumour volume (MTV) of the primary breast 
tumour, even though the absolute values differed slightly between the two modalities [26].  
Data from studies examining the diagnostic accuracy of breast DCE-MRI, hybrid PET-MRI 
and 18F-FDG-PET-CT have shown that DCE-MRI is more sensitive but less specific than 
the 18F-FDG-PET-CT for the evaluation of the primary tumour size and the detection of 
additional ipsilateral or contralateral cancers [16-21]. Studies using the same parameters for 
both modalities utilising the newer modality of hybrid PET-MRI rather than localised breast 
DCE-MRI to compare with PET-CT have yielded variable outcomes [16, 25-28]. Grueneisen 
et al (2015) found that PET-MRI was no better than MRI alone for local tumour staging. 
Furthermore, both PET-MRI and MRI alone delineated local tumour extent more accurately 
than PET-CT [27]. Botsikas et al (2015) showed that MRI alone was more sensitive for the 
primary tumour detection than the PET-MRI, but they found both modalities to be highly 
specific for nodal metastases detection [22].  
A direct correlation of measured sizes has not been possible in other comparative studies of 
PET-CT and MRI where different parameters were used for each modality [17-20, 24, 29-
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35], since the studies focused mainly on metabolic parameters for the 18F-FDG-PET-CT, 
which are not available for DCE-MRI, and similarly for MRI-specific parameters. 
Magometschnigg et al (2015) compared the diagnostic accuracy of the two modalities using 
the SUVmax for 18F-FDG PET-CT and the Breast Imaging Reporting and Data System (BI-
RADS®)lexicon morphology patterns and enhancement kinetics [2] for DCE-MRI. They 
found that 18F-FDG-PET-CT and breast DCE-MRI at 3T demonstrated equal diagnostic 
accuracies in breast cancer diagnosis, however for lesions <10mm, DCE-MRI was more 
sensitive but less specific than 18F-FDG-PET-CT. 
In our study, we used the same parameters for both modalities. Our results showed that the 
mean Dmax and the mean LV were significantly higher when measured on the PET-CT 
images compared with the DCE-MRI. A similar observation was found by Pace et al (2015), 
in which the breast metabolic tumour volume (MTV) was 6% lower on the hybrid PET-MRI 
compared to PET-CT, even though the differences were not statistically significant and there 
was excellent correlation between the measurements [26]. They suggested that a systematic 
bias was responsible for the differences, but noted that the differences fell within 1.96 
standard deviations of the mean and can be considered clinically unimportant. We propose 
a number of possible explanations for this. Firstly, although both modalities were performed 
in the prone position, the breasts hang freely in the dedicated breast coil during an MRI scan 
but tend to be compressed against the table on the prone PET scanning, which may result in 
some distortion of tissue and apparent magnification of the resultant image. Secondly, PET-
CT suffers from a partial volume effect (PVE) which may result in overestimation or 
underestimation of the lesion size [36]. This appears unlikely as an explanation in our data 
since the deviation was unidirectional. Thirdly, intravenous contrast was used for DCE-MRI 
but not for PET-CT, which may contribute to the better delineation of the lesion on the MRI 
than on the PET.  
The correct measurement of breast lesions with either or both PET-CT and MRI is the 
fundamental part of staging and monitoring of treatment in patients with breast cancer [8]. 
The tumour maximum diameter is one of the criteria used in the response evaluation criteria 
in solid tumours (RECIST) version 1.1, which is not only important in clinical practice but 
also in clinical trials evaluation [37]. Studies comparing PET-CT and MRI in breast cancer 
patients receiving neoadjuvant chemotherapy (NAC) also have variable findings [17, 21, 30, 
33, 35, 38]. Some studies showed good correlation between the two modalities for response 
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evaluation [30, 33, 35], whilst others showed MRI to be better than PET-CT [17], others 
showed PET-CT to have better prediction of complete pathological response than MRI in 
luminal B type breast cancer [38]. 
While PET-CT is unlikely to replace breast MRI in clinical practice, it may prove a useful 
adjunct to it [18, 20]. It may also have a place as a staging modality in patients who have 
contraindications to MRI such as those who are claustrophobic and those with an implanted 
pacemaker [39, 40].  
Our study has several limitations. Although our sample was small, we were able to show 
statistical significance; furthermore we note that the larger measure for PET-CT was present 
in every case, suggesting that the observation is real. Secondly, the images were read by 
consensus, and intra-operator and inter-operator differences were not evaluated.  
In conclusion, we have shown that there is a strong correlation in the lesion measurement 
between 18F-FDG-PET-CT and DCE-MRI for both the maximum diameter and the lesion 
volume using the 3-D measuring technique. It would therefore appear that one modality is 
as effective as the other in determining the size of a breast lesion. However, given that there 
was an absolute difference in size between the two modalities, it is important that 
measurements using a single modality are compared; it is inappropriate to compare 
measurements across modalities.  
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FIGURE LEGENDS 
Figure 1  
18F-FDG-PET-CT and breast DCE-MRI images of a 45 year old woman with left breast 
cancer (patient no.6). The measurements for the 3-D volume and the maximum diameter 
demonstrated.  
(a-c): T1 weighted 3-D subtracted DCE-MRI images. a) Axial; b) Coronal; and c Sagittal 
images.  
(d-e): Fused 18F-FDG-PET-CT images. d) Axial; e) Coronal; and f) Sagittal images. 
Figure 2  
Comparison of the measurement of 3-D volume of breast lesions using DCE-MRI and PET-
CT images respectively via linear regression; correlation of determination R2=0.986.  
Figure 3 
Comparison of the measurement of 3-D diameter of breast lesions using DCE-MRI and PET-
CT images respectively via linear regression; correlation of determination R2=0.931. 
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TABLE 1 
Local dynamic contrast-enhanced breast MRI protocol technical parameters. TSE=Turbo Spin Echo; GE=Gradient Echo; STIR=Short Tau 
Inversion Recovery. 
MRI sequence Acquisition 
plane 
Repetition 
time (TR) 
(msec) 
Echo Time 
(TE) (msec) 
Inversion 
time (msec) 
Matrix size Field of 
view (FoV) 
(mm) 
Slice 
thickness 
(mm) 
Voxel size 
(mm) 
Localizer sagittal 7.6 3.53 - 384 x 512 400 6 2.1x1.6x6.0 
T1 pre-contrast GE 3D  axial 8.6 4.70 - 299 x 384 320 1 1.0x0.7x1.0 
T1 GE 3D dynamic sequences ( 
1 pre& 5post contrast)  
axial 9.1 4.76 - 299 x 284 340 1.5 1.1x0.9x1.5 
T1 3D Dixon axial 7.20 first 2.38; 
second 4.76 
- 320 x 320 340 1.8 1.1x1.1x1.8 
T1 fat sat axial 680 10 - 224 x 320 320 4 1.4x1.0x4.0 
T2 STIR axial 5600 59.0 170 314 x 320 340 4 1.1x1.1x4.0 
T2 TSE axial 6100 111 - 384 x 512 320 4 1.7x1.3x4.0 
DWI b values 0 & 800s/mm2 axial 9200 86 180 150 x 192 380 4 2.0x2.0x4.0 
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TABLE 2 
Comparison of 18F-FDG-PET-CT and DCE-MRI in the evaluation of breast lesions in patients with either breast cancer or breast tuberculosis 
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Patient ID  Diagnosis Maximum diameter (cm) Volume (cm3) 
DCE-MRI 18F-FDG-PET-CT DCE-MRI 18F-FDG-PET-CT 
1  TB 5.1 5.8 51.5 64.6 
2 first lesion  TB 12.2 14.9 190.8 234.3 
second lesion TB 4.7 5.3 30.3 46.2 
third lesion  TB 5 5.2 39.4 58.8 
3 TB 11.1 11.7 440.1 380.6 
4 TB 13.9 20 1300.7 1382.2 
5 TB 4.3 6.1 30.7 63.7 
6 Cancer 9.2 10.2 283.7 391.5 
7 Cancer 7.4 8.1 161.8 252.9 
Mean ± SD  8.1 ± 3.6 9.7 ± 5.1 (p=0.032) 280.98 ± 406.8 319.4 ± 421.8 
(p=0.052) 
Correlation factor (R)  0.964 (p<0.0001) 0.993 (p<0.0001) 
Coefficient of 
determination (R2) 
 0.931 (p<0.0001) 0.986 (p<0.0001) 
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FIGURE 2 
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FIGURE 3 
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SYNTHESIS AND DISCUSSION 
INTRODUCTION 
The purpose of this project was to evaluate the prevalence and spectrum of radiological 
manifestations of breast tuberculosis (BTB) in South African patients, drawing on a sample 
from two tertiary-level breast clinics in Durban, South Africa, to identify the radiological 
patterns manifest in these patients with a view to improving the specificity of diagnosis, with 
particular reference to the newer modalities of PET-CT and MRI, and to study the 
radiological markers indicating a satisfactory response to treatment. In the pages which 
follow, we have synthesised our findings into a number of conclusions and 
recommendations. 
CONCLUSION 1 
The prevalence of BTB is low. 
The Addington surgical breast clinic is the major referral centre for the Ethekwini 
Municipality group of hospitals. However, even in this setting, the five-year period 
prevalence of BTB was found to be only 0.3% (Chapter 2). This finding emphasises that 
although the incidence of extrapulmonary tuberculosis (EPTB) is increasing in association 
with high rate of Human Immuno-Deficiency virus (HIV), the breast is still infrequently 
involved (Yang et al. 2004). Our findings are in line with other studies, which found the 
incidence of BTB to be low amongst patients presenting with breast disease (Meerkotter et 
al. 2011; Tewari & Shukla 2005). Shushtari et al. (2011) reported nine BTB cases in a total 
of 2235 over a five year period from 2005-2009. Due to the rarity of the disease, there is 
scanty literature to provide the clinician with adequate evidence based information.  
One consequence of this low prevalence is the difficulty in recruiting large patient cohort for 
study.  Indeed, in the further studies incorporated onto this thesis, we studied a small number 
of patients; a feature common to all previously published studies on this subject (Oh et al. 
1998; Popli et al. 2010). Though ideal, recruitment of meaningfully large cohorts would be 
difficult, and would have to be multicentre, with the consequent problems of a prolonged 
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period of recruitment and the difficulties in overcoming differences between centres, 
particularly in terms of subjectivity in interpretation. 
CONCLUSION 2 
Current classifications of BTB are predominantly clinically based without any radiological 
correlation therefore we provide a descriptive framework based on clinical-radiological 
assessment which may be of more clinical utility. 
Our data identified five clinical-radiological patterns of BTB based on mammography and 
ultrasound findings (Chapter 2). We retrospectively analysed 65 patient records on the 
prevalence study. Our data from the retrospective prevalence study identified the five distinct 
clinical-radiological patterns of BTB as: inflammatory/disseminated; axillary lymphadenitis 
with breast oedema (ALBE); abscess variety; nodular/focal mass; and the isolated axillary 
tuberculous lymphadenitis (IATL). Among the patients who had mammograms, the 
asymmetric density without nodes was the commonest observation in those found with the 
abscess variety on ultrasound. Although clinically IATL was not reported, it was seen in 
12.1 % of mammograms. Our finding of IATL is similar to a smaller retrospective study of 
21 patients with BTB that was done in Johannesburg (Meerkotter et al. 2011). In contrast, 
in studies performed outside South Africa, isolated axillary lymphadenitis was not 
specifically reported as the predominant presenting feature (Mehta et al. 2010; Oh et al. 
1998). It is therefore important that the clinician is aware of the various presentations that 
can occur in the breast affected by TB, especially where TB is endemic like in this setting. 
Our various classifications reinforce the wide spectrum of presentation of BTB lesions. 
Furthermore, although there have been studies (Harris et al. 2006; Meerkotter et al. 2011) 
on the clinical-radiological features of BTB since the clinical classification of the disease by 
Tewari and Shukla (2005), the authors did not commit to any classification. Our data 
provided adequate information to allow us to re-classify the disease into the above 
categories. We therefore propose that the following classification framework be applied to 
BTB for research and clinical purposes: Table 8.1. 
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Pattern Clinical Mammogram 
description 
Ultrasound 
description 
Inflammatory/ 
disseminated 
Diffuse inflammation & 
tenderness  
Non-specific diffuse 
stromal thickening & 
axillary nodes 
Diffuse hypoechoic  
trabecular thickening 
due to oedema& 
axillary nodes 
ALBE Enlarged breast, 
Oedema, no 
inflammation 
Non-specific diffuse 
stromal thickening ± 
axillary nodes 
Diffuse hypoechoic  
trabecular thickening 
due to oedema ± 
axillary nodes 
Abscess Focal tender mass Asymmetric density Complex solid-cystic 
heterogeneous mass 
Nodular/focal 
mass 
Focal firm mass Irregular/smooth focal 
mass density 
Hypoechoic/heterogene
ous solid mass 
IATL Axillary swelling Well defined dense 
mass 
Oval hypoechoic solid 
thick cortex mass 
Table 8.1 Proposed clinical-radiological classification of BTB, based on clinical, 
mammography and ultrasound examination. 
CONCLUSION 3 
The newer modalities of PET-CT and multiparametric MRI are potentially of value in the 
evaluation of BTB. 
Appearances of BTB on 18F-FDG-PET-CT and differentiation from BCA 
We evaluated 18F-FDG-PET-CT findings in five patients with BTB (Chapter 3 and 5). We 
conclude that the two patterns can be encountered on 18F-FDG-PET-CT in patients with 
breast tuberculosis namely: a) the breast only pattern; and b) the combined breast/lymphatic 
pattern; The various patterns appear to have an association with patient clinical condition, 
whereby the breast only pattern is associated with general wellness and less severe disease, 
whereas the combined breast/lymphatic pattern represents the worse end of the spectrum of 
disease severity and debilitation. In the breast only pattern, the metabolic activity is localised 
to the breast region, with no significant association of pulmonary, lymph nodes or other 
organ involvement. The breast only pattern has not been previously described in other 
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studies which evaluated the patterns of TB on 18F-FDG-PET-CT (Martinez et al. 2012; 
Mehta 2012; Soussan et al. 2012). In the combined breast/lymphatic pattern, there was 
predominance of 18F-FDG avid lesions in the breast and widespread lymph nodes as well as 
other EPTB including hepato-splenic, bone and subcutaneous tissues. Although there may 
be evidence of pulmonary TB (PTB), the severity did not qualify for being classified under 
the lung pattern as described by (Soussan et al. 2012). There is limited data in the literature 
about the patterns of TB on 18F-FDG-PET-CT. The lung and the lymphatic patterns were 
reported in the two studies (Martinez et al. 2012; Soussan et al. 2012), in which there was 
an association of the former with predominant pulmonary disease and the latter with more 
severe systemic disease (Martinez et al. 2012; Soussan et al. 2012).  We also found similar 
association between the lymphatic pattern and the severity of the clinical findings. We 
additionally found a new pattern which has not been described previously, the breast only 
pattern. 
Some parameters may play a role in the differentiation between BTB and breast cancer 
(BCA) (Chapter 5). The SUVmax can be used in for this purpose, in which the BCA patients 
displayed significantly higher values than the BTB patients for the breast lesions. This 
finding has similarities to some recent studies that evaluated the role of 18F-FDG-PET-CT 
in differentiating between benign and malignant pulmonary nodules (Van Gomez Lopez et 
al. 2015; Yilmaz & Tastekin 2015). Sadly, the same parameter, the SUVmax, was not useful 
in separating the TB axillary nodes from the malignant ones. This implies that we cannot 
yet prevent the futile biopsy of axillary nodes in patients with BCA. This is in agreement to 
a study done in a similar setting where TB is endemic, in which the SUVmax could not 
differentiate benign from malignant pulmonary nodules (Sathekge et al. 2010). The CT 
Hounsfield units (HU) were not useful in differentiating the breast lesions or the axillary 
nodes.  
We conclude that 18F-FDG-PET-CT has a role, especially in determining the pattern of 
whole body involvement with disease, whereby we described the previously unreported 
breast only pattern. A further role of 18F-FDG-PET-CT is in the provision of a semi-
quantitative differential guide in separating BCA from BTB with the use of SUVmax.  
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Appearances of BTB on DWI, T2W and DCE-MRI and differentiation 
from BCA 
We analysed the MRI of six patients with BTB (Chapters 4 and 6). The use of multi-
parametric MRI qualitative and semi-quantitative parameters has provided us with a guide 
description of the appearances of BTB lesions on this modality, as well as in the differential 
diagnosis between BTB and BCA. We have tabulated these findings in order to provide a 
tool for the reporting radiologist with differentiating features between BTB and BCA, with 
the following two cautions (Table 8.2). 
Caution 1: The features would mainly apply for the common breast cancer pathological type 
of invasive ductal cancers (IDC), other uncommon types may have variable appearances. 
Caution 2: The significance of apparent diffusion coefficient (ADC) and T2 signal intensity 
(T2SI) values in separating BTB from BCA lesions appear to be influenced by whether the 
breast lesion enhancement pattern is mass or non-mass enhancement (NME), the parameters 
showing statistically significant differences between BTB and BCA for the mass pattern but 
not for the NME pattern.  Many studies (Dorrius et al. 2014; Yamaguchi et al. 2015; Zhao 
MRI parameter BTB BCA 
Pre-contrast T1W Hypointense Isointense/hypointense 
Pre-contrast T2W 
morphology 
Hyperintense/mixed signal Hypointense 
Pre-contrast T2W, T2SI 
value 
Higher Lower 
Post contrast DCE-MRI 
(mass pattern) 
Rim-enhancing with no 
internal solid elements 
Rim-enhancing with internal 
solid elements 
Post contrast DCE-MRI 
(non-mass pattern (NME)) 
Ring/rim enhancing axillary 
nodes 
Solid axillary nodes 
DWI ADC value Higher Lower 
Axillary nodes Ring/rim enhancing solid 
Table 8.2 MRI differential diagnosis of breast lesion in a patient suspected of 
having either BTB or BCA. 
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et al. 2015) that used the ADC value to discriminate between benign and malignant breast 
lesion were done on mass pattern, with only few (Imamura et al. 2010; Partridge et al. 2009) 
that evaluated the use of this parameter for both patterns.  Partridge et al found that the ADC 
value was more beneficial for mass pattern than for NME, which is in agreement with our 
finding (Partridge et al. 2009).  
Our finding of BCA pre-contrast T2W hypointense is in line with other studies (Gribbestad 
et al. 1994; Kuhl et al. 1999; Malich et al. 2005). We also found all patients with BTB to 
have ring/rim-enhancing necrotic axillary nodes, the finding that has been reported by other 
authors (Lee et al. 2012; Williams et al. 2010) . There is paucity of literature on the 
appearances of BTB on MRI, Apart from the study done on four patients to differentiate 
BTB from BCA on magnetic resonance spectroscopy (MRS) (Popli et al. 2010) and a case 
report to assess treatment response of one patient with BTB (Fellah et al. 2006), we found 
only one study that was performed on six patients with BTB in 1998 (Oh et al. 1998). Popli 
et al found BTB lesions to have absence of choline peak and presence of strong lipid peak 
(Popli et al. 2010). Oh et al reported similar findings to our study, from a total of seven 
breast lesions, four demonstrated ring/rim enhancement, however in contrast to ours, two 
had internal enhancement, and one lesion did not have any enhancement (Oh et al. 1998). 
Since 1998, there has been significant technological advancement involving all aspects of 
breast imaging, from equipment, to image acquisition and processing. These factors may 
play a role in the discordant reporting between our findings and those of (Oh et al. 1998). 
The ADC value was a good discriminator between the BTB and the BCA group, with the 
latter demonstrating statistically significant lower values than the former (Chapter 6). Our 
results are in agreement with other studies (Imamura et al. 2010; Qu et al. 2015; Woodhams 
et al. 2005; Yabuuchi et al. 2010; Yamaguchi et al. 2015; Yili et al. 2009; Zhao et al. 2015), 
with few exceptions (Chatterjee et al. 2010). Peng et al found intracranial tuberculomas to 
have higher ADC value than high grade gliomas (Peng et al. 2012). In contrast, Chatterjee 
et al found no difference in the ADC values between brain tuberculomas and metastases 
(Chatterjee et al. 2010).  
The T2SI value was a strong discriminator between the BTB and the BCA group, with the 
latter group displaying significant lower values than the former hence this parameter can be 
a valuable marker. The use of quantitative T2SI as a discriminator of malignancy has been 
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evaluated for other body parts other than the breast (Henz Concatto et al. 2015; Peng et al. 
2014). Henz et al found that the mean T2SI ratio and the ADC values were significant in 
differentiating benign from malignant pulmonary nodules in a granulomatous endemic area 
(Henz Concatto et al. 2015). 
We conclude that multiparametric breast MRI appears to add value beyond that of 
conventional imaging modalities in diagnosing BTB, specifically in assigning probabilities 
to the diagnosis of BTB vis a vis BCA and in defining disease extent. 
Defining extent of disease with 18F-FDG-PET-CT and DCE-MRI 
The advantage of 18F-FDG-PET-CT over conventional imaging of mammography, 
ultrasound and chest x-ray (CXR) is the ability to image the whole body instead of only 
imaging the localised body parts of breast and/or chest. It is therefore not surprising that 
more extensive disease spread was seen on 18F-FDG-PET-CT than on conventional imaging, 
the extra sites being the lymph nodes, liver, spleen, skeleton and subcutaneous tissues 
(Chapters 3 and 4). This means that PET-CT can be used as an adjunct to mammography, 
ultrasound and CXR in patients suspected of having more widespread disease. The value 
of 18F-FDG-PET-CT in evaluating the TB disease burden has been mainly studied in patients 
presenting with PTB 
(Coleman et al. 2014) 
 
 (Chen et al. 2014; Soussan et al. 2014; Stelzmueller et al. 2015). Excluding case reports, 
there are few studies that evaluated the value of 18F-FDG-PET-CT in extrapulmonary TB 
(EPTB), and none of the sites mentioned was breast (Dureja et al. 2014; Martinez et al. 
2012; Stelzmueller et al. 2015). Stelzmueller et al compared the diagnostic accuracy of PET 
and CT components of 18F-FDG-PET-CT in 35 patients with PTB or EPTB.  The authors 
found comparable diagnostic performance on the initial baseline and follow up scans even 
though 18F-FDG-PET demonstrated more abnormal findings than CT (Stelzmueller et al. 
2015).  
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Breast DCE-MRI has many advantages over mammography and ultrasound including: better 
soft tissues contrast; ability to include chest wall in the imaging field; the use of intravenous 
(I.V.) contrast to improve lesion detection and characterisation (Machida et al. 2015). Again, 
it is not surprising that more local disease extent including chest wall involvement was 
revealed on DCE-MRI, yet was not seen on mammography and/or ultrasound (Chapter 4). 
However, unlike 18F-FDG-PET-CT, DCE-MRI is focused on the breast/chest region only 
hence distant disease cannot be assessed.  
Our conclusion is that both 18F-FDG-PET-CT and DCE-MRI are valuable in providing the 
clinician with more information about disease extent than would not be possible with 
conventional imaging. 
Monitoring response of BTB to anti-tuberculous therapy using 18F-FDG-
PET-CT and MRI 
Response to treatment of BTB can be monitored using parameters derived from these two 
modalities.  
Our conclusions following image review of five patients with BTB who had both 18F-FDG-
PET-CT and MRI at start of anti-tuberculous treatment (ATT) and at 4 months of treatment 
(Chapter 3 and 4) are that the breast lesion or axillary node maximum standardised uptake 
value (SUVmax) and maximum diameter (Dmax) values can be used to separate the responders 
from the non-responders, the latter group displaying higher values than the former at baseline 
scan which demonstrated significant increase at 4 months follow-up scan. The SUVmax 
finding is similar to other 18F-FDG-PET-CT studies done on PTB (Coleman et al. 2014; 
Sathekge et al. 2012; Sathekge et al. 2011) and EPTB (Dureja et al. 2014; Martinez et al. 
2012) patients, hence it is used as a marker in TB treatment monitoring. Sathekge et al found 
the TB lymph nodes diameter to have significant role in differentiating the responders from 
the non-responders, in which the larger sized nodes were seen in non-responders (Sathekge 
et al. 2012). 
The number of lymph node basins was not useful for separating the responders and the non-
responders. In contrast, in a study done to predict response to first line ATT in TB-HIV co-
infected patients, five or more lymph node basins could separate responders from non-
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responders with a sensitivity and specificity of 88% and 81% (Sathekge et al. 2011). Other 
MRI parameters of ADC value and T2SI value were not useful for treatment monitoring.  
We conclude that response to ATT may be monitored using 18F-FDG-PET-CT and/or MRI 
using the following parameters: SUVmax and Dmax for 18F-FDG-PET-CT and Dmax for MRI. 
Other parameters by contrast are unhelpful. We did not directly compare the older modalities 
with the newer modalities, since 18F-FDG-PET-CT and MRI were used to assess interval 
change at 4 months, whereas conventional modalities were only assessed on completion of 
treatment, at 9 months. A direct comparison is now indicated, given the lower cost and wider 
availability of conventional imaging. 
Correlation of lesion size determined by 18F-FDG-PET-CT and DCE-
MRI respectively 
Either of these two modalities can be used in staging and treatment monitoring provided one 
modality is used consistently. We observed a strong correlation between the two modalities 
(Chapter 7). The measured lesion volume (LV) and maximum diameter (Dmax) of the breast 
lesions were however higher on 18F-FDG-PET-CT than on DCE-MRI, suggesting that 
absolute sizes should not be compared across modalities. We have suggested that differences 
in patient positioning, particularly the compression of the breast resulting from the 
undedicated prone position 18F-FDG-PET-CT scanning as opposed to dedicated breast coil 
prone scanning on DCE-MRI, may account for this, as may the use of intravenous (I.V.) 
contrast for DCE-MRI. The partial volume effect suggested by (Anouan et al. 2015) does 
not appear to be a factor. 
We conclude that apart from these slight differences between the two modalities, the 
excellent correlation implies that either modality can be used consistently in treatment 
monitoring. Although one modality cannot replace another, there are circumstances where 
either investigation cannot be used or is contra-indicated. Examples include patients who 
have MRI phobia and those with in situ pacemakers (Kodali et al. 2013; Mann et al. 2015). 
Our findings imply that 18F-FDG-PET-CT can be an alternative treatment monitoring and/or 
staging investigation in these patients.  
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POTENTIAL BENEFITS OF THIS RESEARCH 
We re-classified BTB into five distinct clinical-radiological patterns on mammography and 
ultrasound. We further classified it into two patterns on 18F-FDG-PET-CT and described a 
new pattern which has not been previously reported. We described typical morphological 
appearances of BTB on multi-parametric MRI. We further identified potential markers for 
treatment response monitoring on both 18F-FDG-PET-CT, DCE-MRI, T2W and DWI-MRI. 
It is hoped that this knowledge will aid the practicing clinician and the reporting radiologist 
to include the disease in the differential diagnosis when they encounter similar appearances. 
Knowledge of typical radiological appearances in the right setting will guide the radiologist 
towards the correct diagnosis. The identification of potential markers can play a role in 
effective monitoring of more severe infection.  
FUTURE RESEARCH  
The retrospective study (objective 1) can be extended to incorporate survival analysis of the 
cohort, which would require further funding and resources to track all the participants. In the 
analysis of the response to treatment (objectives 3 and 4), both studies can be further 
enhanced with the inclusion of control group consisting of TB patients who do not have 
BTB. In the two studies that evaluated the differences between BCA and BTB (objectives 5 
and 6), a more in depth quantitative analysis can be performed with the use of newer 
quantitative software packages which we did not have funding for. 
STUDY LIMITATIONS 
Small sample size 
This is difficult to avoid given the low prevalence of BTB. Many of our findings should be 
regarded as preliminary, and will require verification. This will require a large multicentre 
study. We were also limited in the number of scans that could be performed by the expense 
of these investigations. It would for example have been useful to repeat the 18F-FDG-PET-
CT and MRI study on completion of treatment in addition to the 4-month mark to identify 
further evolution of appearances. 
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Software 
A higher level of quantitative analysis would be possible by utilising more advanced 
software packages such as the dedicated advanced breast MRI post-processing Syngo-via 
MR Brevis (Siemens, Erlangen, Germany) and the imaging biomarker experts Icometrix 
(Icometrix, Leuven, Belgium) quantitative imaging tools, access to which was limited by 
funding. Such analysis of the stored images may be possible in future should such software 
become available.  
RECOMMENDATIONS 
The study findings suggest the following recommendations: 
1. The prevalence of BTB, though low, is not zero. It is important that clinicians and 
radiologists are primed to recognise the possibility of BTB and to respond 
appropriately in terms of diagnosis. The papers arising from this project will provide 
a valuable addition to the literature to guide clinicians under such circumstances.  
2. The potential value of 18F-FDG-PET-CT and MRI in the investigation of BTB 
should be recognised. 
3. Patients with BTB suspected of having disease beyond the breast itself should be 
considered for 18F-FDG-PET-CT and/or MRI imaging given their superiority in 
detecting extensive disease 
4. When BTB and BCA appear in the differential diagnosis, 18F-FDG-PET-CT and/or 
MRI imaging may assist in their differentiation. This may be particularly useful in 
the patient with known TB elsewhere who presents with a breast lesion. 
5. When there is discordant result between clinical appearances and pathology, MRI 
should be considered.  
6. All BTB patients who are clinically not responding to ATT at the follow-up 
appointment should be considered for 18F-FDG-PET-CT and/or MRI imaging.   
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Aims and objectives
Purpose:
Introduction:
It is estimated that over 1 billion people worldwide have tuberculosis (TB) [1]. However,
breast tuberculosis (BTB) is a rare condition. The incidence is quoted as less than 0.1%
of all surgical breast lesions seen in developed countries and 3-4.5% of breast lesions in
countries where BTB is endemic [2-5], although even in this setting, carcinoma is far more
commonly encountered [6]. While BTB is considered a manifestation of extrapulmonary
tuberculosis (EPTB), it represents only about 0.1 % of the disease burden of EPTB.
However, there has been a resurgence of EPTB due to Human Immune Deficiency (HIV),
with estimated incidences as high as 50% in countries where HIV infection is endemic [7].
Both breasts are equally affected. In approximately 3% of cases, tuberculosis may be
found bilaterally [8]. Up to 70% of cases may have associated axillary lymphadenopathy,
often with visible axillary swelling [9]. Constitutional symptoms are unusual in the absence
of systemic and particularly pulmonary tuberculosis [6].
There are no clinical or radiological features which are absolutely diagnostic of breast
tuberculosis. The diagnosis is usually readily confirmed by biopsy with histology or fine
needle aspiration and staining for acid-fast bacilli (AFB), Mycobacterial culture or the
polymerase chain reaction (PCR). Whereas the main differential diagnosis is carcinoma,
other considerations are idiopathic granulomatous mastitis and fungal infections. Most
patients respond to standard anti-tuberculous therapy (ATT) [10]. It has been suggested
that patients in endemic areas presenting with a breast mass in whom histology reveals
granulomatous inflammation, should receive ATT, even if culture results are negative for
TB [11]. There have been reports that occasionally sinuses, fistulae and deformities may
require primary localised excision or simple mastectomy, but this is not standard care [6].
The aim of our study was to identify different radiological patterns of BTB, to assess
available treatment options and response to treatment.
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Methods and materials
We identified 64 patients with histological or cytological confirmed diagnosis of breast
tuberculosis. One patient with discharging axillary nodes and breast oedema was
included even though cytology was not confirmatory. Therefore 65 patients were included
in the data analysis. Patients were diagnosed between 2000 and 2013. Collection of data
from the Breast Clinic was performed. The study was approved by the institutional review
board.
Retrospective chart and radiology review focused on demographic, clinical,
mammographic and ultrasound patterns, diagnostic and treatment methods.
Mammograms Medio-Lateral Oblique (MLO) and Cranio-Caudal (CC) views were
obtained from a standard analogue mammographic unit (+/- digital processing).
Ultrasound images were obtained on the standard unit using 7.5 - 12.5 MHz linear probe.
Classification of mammographic and ultrasound patterns is shown in (Fig. 1 and Fig. 2)
respectively.
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Fig. 1: Mammographic patterns.
References: Diagnostic Radiology, Nelson R Mandela School of Medicine - Durban/ZA
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Fig. 2: Ultrasound patterns.
References: Diagnostic Radiology, Nelson R Mandela School of Medicine - Durban/ZA
Histological and microbiological diagnosis was done by obtaining core biopsy samples
using 14Gauge needle. Cytological diagnosis was done by Fine Needle Aspiration (FNA).
Lesion localisation was achieved by either palpation or ultrasound guided.
Statistical analysis
Medcalc statistical software using descriptive statistics was used to analyse results.
Images for this section:
200
Page 6 of 39
Fig. 1: Mammographic patterns.
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Fig. 2: Ultrasound patterns.
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Results
Demographics and clinical presentation
Summary of demographics and clinical presentation is shown in Table 1.
Characteristics Total (n = 65), n (%)
Gender
Female (98.5%) 64 (98.5)
Male (1.5%) 1 (1.5)
Age at Presentation
Range 23yr - 69 yr
Mean (SD) 38.5yr (10.3
Side
Left 30 (46.2)
Right 33 (50.8)
Unknown 2 (3.1)
Axillary nodes
Yes 21 (33.9)
No 41 (66.1)
Table 1: Age range was 23 to 69 years with a mean age of 38.5 years. There was no
right or left side preference. Almost one third of patients had associated axillary nodes.
References: Diagnostic Radiology, Nelson R Mandela School of Medicine - Durban/ZA
Clinical Presentation
Proportions of clinical patterns is depicted in (Fig. 3). The most common presentation
(40%) was an inflammatory mass, also termed diffuse/disseminated form. The second
and third presentations were oedema with adenitis and the nodular (focal mass), both
of which occurred in almost equal proportions, being 24.6% and 26.2% respectively.
203
Page 9 of 39
Although on clinical assessment, the abscess variety was reported in only n =2 (3.1%)
cases, on ultrasound this presentation was the most common, seen in n =16 (39%), with
or without adenitis. Based on our findings we propose to classify BTB into four forms;
• i) Inflammatory mass/disseminated,
• ii) Oedema with adenitis,
• iii) Abscess
• iv) Nodular (focal mass).
• Classifications i), iii, and iv) can occur with or without associated axillary
lymphadenopathy.
Fig. 3: Clinical presentation proportions.
References: Diagnostic Radiology, Nelson R Mandela School of Medicine - Durban/ZA
Associated clinical features
Record of associated clinical features are recorded in Table 2.
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Characteristics n (%)
History pulmonary TB (n = 47)
CXR normal 32 (49.2)
CXR abnormal 15 (23.1)
Pregnant/lactating (n = 65)
No 64 (98.5)
Yes 1 (1.5)
HIV Status (n = 47)
Negative 12 (18.5)
Positive 34 (52.3)
Refused testing 1 (1.5)
Table 2: Amongst all 65 patients, only one was lactating, whereas 34 were HIV positive.
Whilst 47 patients had history of prior pulmonary TB, only 15 had radiological evidence
of either prior or concurrent pulmonary TB.
References: Diagnostic Radiology, Nelson R Mandela School of Medicine - Durban/ZA
Radiological features
Mammography and ultrasound findings are summarised in (Fig. 4 and Fig. 5)
respectively.
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Fig. 4: Of 33 patients who had mammograms, 16 demonstrated ipsilateral or bilateral
axillary lymphadenopathy. Asymmetric density pattern was seen in 13 cases.
References: Diagnostic Radiology, Nelson R Mandela School of Medicine - Durban/
ZA
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Fig. 5: Ultrasound was performed in 41 patients. The commonest pattern was abscess
variety in 16 cases (39%).
References: Diagnostic Radiology, Nelson R Mandela School of Medicine - Durban/ZA
Clinical-radiological patterns
i) Inflammatory/Disseminated
This pattern was the most common clinical presentation. However, amongst those who
had mammograms, this pattern was seen in 21.2% (Fig. 6).
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Fig. 6: Inflammatory/Disseminated Breast tuberculosis. Images taken from various
patients. A. Mammogram MLO views. The right breast is enlarged. Non-specific diffuse
stromal thickening and skin is oedema. B. Left breast photograph. Inflammatory skin
change. C. Ultrasound images showing diffuse trabecular thickening with oedema as
hypoechoic bands in between hyperechoic fibro-fatty tissue.
References: Diagnostic Radiology, Nelson R Mandela School of Medicine - Durban/ZA
We noted that all cases with inflammatory/disseminated form also had nodes. This
supports the hypothesis that this form may be due to either reactive oedema, or
retrograde spread from the axillary lymph nodes [12]. To date, there has not been a
study to specifically determine whether AFBs are present within the oedematous or
diffusely inflamed breast. The major differential diagnosis of this form is inflammatory
breast cancer. However, the combination of an inflammatory breast lesion and sinuses
or fistulae favours BTB from cancer [13]. On ultrasound some appeared as diffuse
trabecular thickening and oedema (Fig. 6C), whereas others demonstrated a diffuse
inflammatory mass.
Corresponding Magnetic Resonance Imaging (MRI) for the inflammatory BTB pattern
appears as enlarged and oedematous breast (Fig. 7).
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Fig. 7: Breast MRI T2 STIR axial image. A. The right breast has diffuse trabecular
hyperintensity, more intense posteriorly abutting the pectoral muscles. B. Skin oedema.
References: Diagnostic Radiology, Nelson R Mandela School of Medicine - Durban/ZA
ii) Oedema with adenitis
The clinical presentation of oedema was noted in 24.6% (Fig. 8). Ultrasound pattern of
oedema was seen in n=11 (26.9%). This pattern can be found in other forms of mastitis.
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Fig. 8: A. Mammogram MLO views. The left breast is enlarged. Skin oedema and
enlarged left axillary nodes are evident. B. Left breast photograph from same patient.
The Left breast is larger than the right. (Note: No evidence of skin inflammation, in
comparison to the inflammatory pattern).
References: Diagnostic Radiology, Nelson R Mandela School of Medicine - Durban/ZA
iii) Abscess variety
Even though clinical evaluation classified abscess variety in only 3.1%, ultrasound
showed this pattern to be the most common, seen in n= 18 (39%), with or without adenitis.
On ultrasound it appears as complex solid-cystic heterogeneous hypoechoic mass and
fluid collections. In our study, asymmetric density was the commonest mammographic
pattern, n= 13 (39.4%) associated with this classification. The differential diagnosis is
that of a pyogenic abscess, and indeed some of our patients had received antibiotics
treatment, it was only after lack of response to this treatment that the diagnosis of
tubercular abscess was considered. It is therefore important to obtain sample specifically
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for TB analysis in all cases of non-lactational breast abscess, even if there is no history
of TB elsewhere.
iv) Nodular (focal mass)
Clinically this form presented as a focal mass. On mammogram the focal mass opacities
had variable outline, some had smooth margins, whilst others were irregular. Some were
single, whereas others were multiple (Fig. 9A and B).
Fig. 9: Nodular form breast tuberculosis. Mammogram MLO views. A. At presentation.
Multiple rounded mass opacities in right breast, and enlarged dense right axillary
nodes. B. After 4 months of treatment with ATT. One small round mass opacity
remains in upper part.
References: Diagnostic Radiology, Nelson R Mandela School of Medicine - Durban/ZA
This was the third commonest mammographic pattern seen in 18.2% of patients. On
ultrasound this form appeared as a hypoechoic solid or heterogeneous mass with a
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variable outline ranging from well-defined round to irregular. Lesion size based on
ultrasound ranged from 0.9cm - 6.1cm. The differential diagnosis of this form can
range from benign fibroadenoma to breast cancer depending on the lesion character on
imaging. We did not find microcalcification to be a feature in our study.
v) Tuberculous lymphadenitis
Although isolated lymphadenitis was not reported on clinical presentation, it was seen
in n=4 (12.1%) of mammograms and n= 1 (2.4%) of ultrasounds examinations. Nodes
were intramammary, axillary or both (Fig. 10).
Fig. 10: Tuberculous lymphadenitis. A. Left axilla enlarged nodes discharging onto
skin sinuses. B. Ultrasound Doppler, hilum vessel and thick cortex seen. C. Ultrasound
shows node with thick 7mm cortex (callipers). D. Breast MRI T1 post contrast axial
image. Right axillary nodes (LN) have peripheral rim enhancement and central low
signal (PRECLO).
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References: Diagnostic Radiology, Nelson R Mandela School of Medicine - Durban/ZA
Intra-mammary nodes appeared as well defined round dense masses on mammogram.
These can be confused with a breast mass when they are solitary. Radiological
differentiation of tuberculous axillary nodes from metastatic nodes remains difficult. In
our series axillary nodes appeared as oval, hypoechoic solid masses with thick cortices
and loss of normal fatty hilum. This ultrasound appearance cannot be differentiated from
that of a malignant or metastatic lymph node. Another author described nodes to have
peripheral enhancement with central low attenuation (PRECLO) on PET/CT [14].
Pathology
Histology diagnosis was 94% sensitive compared to 28% for cytology (Fig. 11).
Fig. 11: Sensitivity for FNAC was 28% compared to 94% for histology. Necrotising
granulomatous inflammation was seen in histology specimens.
References: Diagnostic Radiology, Nelson R Mandela School of Medicine - Durban/ZA
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Diagnosis was confirmed by the presence of Acid Fast Bacilli (AFB) and caseating
granulomas (Fig. 12).
Fig. 12: A. 400x (High power) magnification. Clumps of acid-fast bacilli (red against
a blue background) on Ziehl-Neelsen stain. B. Granuloma showing multinucleated
histiocytic giant cells (yellow arrow), epitheliod histiocytes (blue arrow) and
lymphocytes on the periphery (green arrow).
References: Diagnostic Radiology, Nelson R Mandela School of Medicine - Durban/ZA
In support of the literature, the yield of AFB in our study was low, being positive in
10.3% of cytology and 29.6% of histology specimens (Fig. 13). A single histological AFB
detection was by polymerase chain reaction (PCR). Harris et al reported a 2% rate of
positive Ziehl-Neelsen (ZN) smears for AFB from the tuberculous breast abscess fluid
[15]. Furthermore, AFB-positive smear is not always adequate for a definitive diagnosis
of M. tuberculosis, as it should be differentiated from other Mycobacterium species [16].
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Fig. 13: Detection of AFB's in pathology samples.
References: Diagnostic Radiology, Nelson R Mandela School of Medicine - Durban/ZA
Treatment methods
Summarised in (Fig. 14).
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Fig. 14: Amongst all 65 patients, 59 received medical treatment comprising of 9
months of standard anti-TB treatment (ATT). Three patients received both medical and
surgical intervention involving abscess drainage, whilst three were lost and were never
treated following diagnosis.
References: Diagnostic Radiology, Nelson R Mandela School of Medicine - Durban/ZA
Treatment outcome
Summarised in (Fig. 15).
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Fig. 15: Of those treated, 72.7% obtained full resolution, 25% did not complete
treatment, and 2.3% died (n=1).
References: Diagnostic Radiology, Nelson R Mandela School of Medicine - Durban/ZA
Assessment of response to treatment was done by clinical examination and repeat of
radiological investigations, including either ultrasound, mammography or both modalities.
Although there are no documented criteria for radiological response, drug resistance
may be suspected when lesions fail to reduce in size, or change their appearance on
ultrasound or mammography. Ultrasound is especially useful in monitoring the abscess
variety, to detect residual fluid collections. In single studies, both MRI [17] and PET CT
[14] have shown promise as tools for monitoring response.
Images for this section:
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Fig. 3: Clinical presentation proportions.
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Fig. 4: Of 33 patients who had mammograms, 16 demonstrated ipsilateral or bilateral
axillary lymphadenopathy. Asymmetric density pattern was seen in 13 cases.
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Fig. 5: Ultrasound was performed in 41 patients. The commonest pattern was abscess
variety in 16 cases (39%).
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Fig. 6: Inflammatory/Disseminated Breast tuberculosis. Images taken from various
patients. A. Mammogram MLO views. The right breast is enlarged. Non-specific diffuse
stromal thickening and skin is oedema. B. Left breast photograph. Inflammatory skin
change. C. Ultrasound images showing diffuse trabecular thickening with oedema as
hypoechoic bands in between hyperechoic fibro-fatty tissue.
221
Page 27 of 39
Fig. 7: Breast MRI T2 STIR axial image. A. The right breast has diffuse trabecular
hyperintensity, more intense posteriorly abutting the pectoral muscles. B. Skin oedema.
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Fig. 8: A. Mammogram MLO views. The left breast is enlarged. Skin oedema and
enlarged left axillary nodes are evident. B. Left breast photograph from same patient. The
Left breast is larger than the right. (Note: No evidence of skin inflammation, in comparison
to the inflammatory pattern).
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Fig. 9: Nodular form breast tuberculosis. Mammogram MLO views. A. At presentation.
Multiple rounded mass opacities in right breast, and enlarged dense right axillary nodes.
B. After 4 months of treatment with ATT. One small round mass opacity remains in upper
part.
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Fig. 10: Tuberculous lymphadenitis. A. Left axilla enlarged nodes discharging onto skin
sinuses. B. Ultrasound Doppler, hilum vessel and thick cortex seen. C. Ultrasound shows
node with thick 7mm cortex (callipers). D. Breast MRI T1 post contrast axial image. Right
axillary nodes (LN) have peripheral rim enhancement and central low signal (PRECLO).
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Fig. 11: Sensitivity for FNAC was 28% compared to 94% for histology. Necrotising
granulomatous inflammation was seen in histology specimens.
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Fig. 12: A. 400x (High power) magnification. Clumps of acid-fast bacilli (red against a blue
background) on Ziehl-Neelsen stain. B. Granuloma showing multinucleated histiocytic
giant cells (yellow arrow), epitheliod histiocytes (blue arrow) and lymphocytes on the
periphery (green arrow).
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Fig. 13: Detection of AFB's in pathology samples.
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Fig. 14: Amongst all 65 patients, 59 received medical treatment comprising of 9 months
of standard anti-TB treatment (ATT). Three patients received both medical and surgical
intervention involving abscess drainage, whilst three were lost and were never treated
following diagnosis.
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Fig. 15: Of those treated, 72.7% obtained full resolution, 25% did not complete treatment,
and 2.3% died (n=1).
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Conclusion
The varied clinical and radiological presentations of breast tuberculosis have been
demonstrated. Early diagnosis can lead to full response following treatment with
standard anti-TB treatment, averting more invasive surgical treatment or even breast
disfigurement. The practising clinician requires an awareness of these patterns and a
high index of suspicion if misdiagnosis and inappropriate management is to be avoided.
Limitations
Due to the study being retrospective, the data regarding follow up post completion of
treatment was not complete, even though patients were scheduled for further visits.
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